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Introduction: Unless women start effective contraception after using emergency contraception, they
remain at risk of unintended pregnancy. Most women in the UK obtain emergency contraception
from community pharmacies that are unable to provide ongoing contraception (apart from barrier
methods which have high failure rates). This means that women need an appointment with a general
practitioner or at a sexual and reproductive health clinic. We conducted a pragmatic cluster
randomised cohort crossover trial to determine whether or not pharmacist provision of a bridging
supply of a progestogen-only pill plus the invitation to attend a sexual and reproductive health clinic
resulted in increased subsequent use of effective contraception (hormonal or intrauterine).
Methods: Twenty-nine pharmacies in three UK cities recruited women receiving emergency contraception
(levonorgestrel). In the intervention, women received a 3-month supply of the progestogen-only pill
(75 µg of desogestrel) plus a card that provided rapid access to a local sexual and reproductive health
clinic. In the control arm, pharmacists advised women to attend their usual contraceptive provider.
The primary outcome was reported use of an effective contraception (hormonal and intrauterine methods)
at 4 months. Process evaluation was also conducted to inform any future implementation.
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Results: The study took place December 2017 and June 2019 and recruited 636 women to the
intervention (n = 316) and control groups (n = 320). There were no statistically significant differences
in demographic characteristics between the groups. Four-month follow-up data were available for
406 participants: 63% (198/315) of the control group and 65% (208/318) of the intervention group.
The proportion of participants reporting use of effective contraception was 20.1% greater (95% confidence
interval 5.2% to 35.0%) in the intervention group (58.4%, 95% confidence interval 48.6% to 68.2%) than
in the control group (40.5%, 95% confidence interval 29.7% to 51.3%) (adjusted for recruitment period,
treatment arm and centre; p = 0.011). The proportion of women using effective contraception remained
statistically significantly larger, when adjusted for age, current sexual relationship and history of past
use of effective contraception, and was robust to the missing data. There were no serious adverse events.
Conclusion: Provision of a bridging supply of the progestogen-only pill with emergency contraception
from a pharmacist and the invitation to a sexual and reproductive health clinic resulted in a significant
increase in self-reported subsequent use of effective contraception. This simple intervention has the
potential to prevent more unintended pregnancies for women after emergency contraception.
Trial registration: Current Controlled Trials ISRCTN70616901.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 27. See the NIHR Journals Library website for further project information.
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The emergency contraceptive pill can prevent pregnancy following unprotected sex or a burst condom;however, unless women start a regular method of contraception they remain at risk of pregnancy.
Most women obtain emergency contraception from a community pharmacy (chemist), but then require
an appointment with a general practitioner or at a sexual and reproductive health clinic for ongoing
contraception. Getting an appointment can take time and unintended pregnancies can occur during
this time.
If a pharmacist could give women a small supply of a progestogen-only pill or ‘mini-pill’ with their
emergency contraception, together with help to get an appointment at a clinic, then this might help
more women to start effective contraception.
We undertook a study in 29 pharmacies in Lothian, Tayside and London among women receiving
emergency contraception. Pharmacists provided either their standard advice about contraception
(control group) or the intervention. The intervention was a 3-month supply of the progestogen-only
pill plus a rapid-access card, which, if presented at a sexual and reproductive health clinic, would help
women get an appointment for contraception. The order in which the pharmacy provided either control
or intervention was randomised. We conducted telephone interviews with the women 4 months later
to find out what contraception they were using.
A total of 636 women took part in the study, 316 in the intervention group and 320 in the control group.
The proportion who said that they were using an effective method of contraception was around 20% larger
in the intervention group. In addition, fewer women in this group said that they had used emergency
contraception again. This study shows that community pharmacy provision of a small supply of progestogen-
only pills and the invitation to attend a sexual and reproductive health clinic results in a large increase in the
use of effective contraception after emergency contraception. If this became routine practice then it could
help prevent unintended pregnancies.
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Most women who use emergency contraception in the UK access it from a community pharmacy.
It is important that women start an effective ongoing method of contraception after emergency
contraception if they do not want to become pregnant. However, pharmacists cannot usually provide
contraception (except condoms) without a prescription. This means that to start an effective contraceptive
(e.g. implant, oral contraceptive pill, etc.) women must go to a general practitioner or a sexual and
reproductive health clinic. Getting an appointment is not always easy and can take time, and some women
become unintentionally pregnant during this time. This trial aimed to test whether or not a community
pharmacy-based intervention designed to facilitate uptake of effective contraception after emergency
contraception increased the uptake of effective contraception 4 months later, compared with standard
care alone. The intervention consisted of a supply of the progestogen-only pill plus the invitation of rapid
access to a sexual and reproductive health clinic. The hypothesis was that the progestogen-only pill would
provide temporary contraception (known as ‘bridging contraception’) until women could obtain their
preferred method of contraception from a general practitioner or a sexual and reproductive health clinic.
The rapid-access component facilitated access to a local sexual and reproductive health clinic where a full
range of methods of contraception were available.
Design
This was a pragmatic cluster randomised cohort crossover trial. Community pharmacies were cluster
randomised to provide the intervention followed by control or vice versa. The Bridge-it study included
a multimethod process evaluation to assess implementation, mechanisms of change and context to
better understand the effectiveness of the trial.
Setting
Twenty-nine community pharmacies in Scotland and England (Lothian, London and Tayside).
Target population
The community pharmacist assessed the medical eligibility of women (aged ≥ 16 years) presenting for
emergency contraception and provided this (levonorgestrel) in accordance with normal practice.
Health technologies being assessed
The intervention consisted of provision of a 3-month supply of the progestogen-only pill (75 µg of
desogestrel provided by pharmacists using a patient group direction) to be started the day after emergency
contraception, together with a rapid-access card, which, on presentation at the local sexual and
reproductive health clinic, helped women to be seen as a drop-in patient for advice and the provision of
ongoing contraception, including long-acting reversible methods (i.e. implant, intrauterine and injectable).
The control was standard care (which was advice about accessing ongoing contraception from a general
practitioner or sexual and reproductive health clinic) with emergency contraception from the pharmacy.
Standard care was characterised by a mystery shopper exercise that was undertaken in participating
pharmacies before the control period of the trial.
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Methods
In the intervention group, pharmacists provided women with the progestogen-only pill and instructions
for its use. In addition, pharmacists advised women that on presenting the rapid-access card to the
local sexual and reproductive health service they would be seen as a drop-in patient for ongoing
contraception. In the control group, pharmacists advised women to go to their general practitioner or a
sexual and reproductive health clinic for ongoing contraception. All women completed a questionnaire
on their method of contraception at 4 months. This was completed as a telephone interview with a
research nurse or, if preferred, by a self-completed web-based survey. Serious adverse events were
also collected at this 4-month follow-up. The main analysis was based on the intention-to-treat principle.
Baseline and follow-up data were summarised using the mean (standard deviation) or median (interquartile
range), where appropriate, for continuous variables. Discrete variables were summarised with numbers
and percentages. The primary outcome (i.e. the proportion of events in each cluster period) was
analysed using linear regression, with cluster as a fixed effect. The main analysis was adjusted for mean
age, percentage of participants who are in an ongoing sexual relationship and percentage of participants
who have used effective contraception methods previously.
A process evaluation of the intervention was conducted to assess implementation, fidelity and reach.
The process evaluation comprised quantitative and qualitative data collection, including review of training
materials; observation of training; protocol adherence checklists, and recruitment and monitoring forms;
and semistructured telephone interviews with participants (n = 36), pharmacists (n = 22) and sexual and
reproductive health service providers (n = 5). A standardised training observation form was used to guide
observations, with data transcribed into Microsoft Word (Microsoft Corporation, Redmond, WA, USA),
thematic analysis conducted and descriptive summaries written. Thirteen training sessions in Scotland
were observed by the process evaluation research assistant and the study trainers completed the
observation forms after each training session in London. Relevant data from the pharmacist eligibility
screening logs and from the 4-month follow-up surveys were entered into statistical software package
IBM SPSS Statistics V.25 (IBM Corporation, Armonk, NY, USA) and descriptive analysis was conducted.
Interview data were audio-recorded, transcribed verbatim and anonymised. Data analysis was undertaken
using ‘framework analysis’, a method with proven validity and reliability, to ensure systematic thematic
analysis and to facilitate synthesis of key themes. Constant comparison was carried out to ensure that
the analysis represented all perspectives and negative (‘deviant’) cases. All process data were analysed
independently from the outcome data and were documented before the outcomes were known.
Outcomes
The primary outcome was self-reported effective contraception use (hormonal and intrauterine)
at 4 months (intervention group vs. control group). Subanalysis was use of long-acting reversible
contraception in both groups. Secondary outcomes included cost-effectiveness of the intervention
(to be reported later) and the proportion of women in each group having undergone an abortion
within 12 months, using record linkage from participants to national registries (to be reported later).
Process evaluation examined the reasons that the intervention worked or did not work to inform any
future implementation.
Results
The study took place December 2017 and June 2019 and recruited 636 women to the intervention
(n = 316) and control groups (n = 320). There were no statistically significant differences in demographic
characteristics between the groups. Four-month follow-up data were available for 198 (63%) women
in the intervention group and 208 (65%) women in the control group. The proportion of participants
reporting use of effective contraception was 20.1% greater (95% confidence interval 5.2% to 35.0%)
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in the intervention group (58.4%, 95% confidence interval 48.6% to 68.2%) than in the control group
(40.5%, 95% confidence interval 29.7% to 51.3%) (adjusted for recruitment period, treatment arm
and centre; p = 0.011). The proportion of women using effective contraception remained statistically
significantly larger when adjusted for age, current sexual relationship and history of past use of effective
contraception, and was robust to the missing data. Long-acting reversible contraception method use
was not statistically significantly different between the intervention group (13/198, 6.6%) and the
control group (23/208, 11.1%) (95% confidence interval –10.04% to 1.05%; p = 0.112).
The mystery shopper exercise undertaken to describe ‘standard care’ for the control group, concerning
the request for emergency contraception at a community pharmacy, showed that, although pharmacists
were generally helpful, obtaining emergency contraception was not always easy, waiting times were
sometimes long, consultations were short and privacy was not always guaranteed. In addition, less than
half of the pharmacists in the mystery shopper exercise gave any advice about ongoing contraception.
In the process evaluation, the accessibility and convenience of the pharmacy setting was highlighted as
pivotal to making effective contraception more accessible. The intervention was acceptable to pharmacists
and sexual and reproductive health providers, and was seen as an important way to develop and improve
access to contraception and reduce repeat emergency contraception use. Reflections of implementation
indicate that fidelity of delivery was, on the whole, achieved in the pharmacy context. A range of cross-
cutting challenges to implementation emerged that were specific to the community pharmacy and the
sexual and reproductive health context (e.g. high workloads, understaffing, changing priorities), which
had an impact on delivery. Participants’ accounts highlighted that providing a bridging supply of the
progestogen-only pill with emergency contraception from the pharmacy as routine practice may have
a positive impact on knowledge of contraception and contraceptive practices in the short term and,
potentially, in the longer term by overcoming existing barriers to access and increasing confidence in
accessing contraception and managing risk. Persistent barriers to accessing and using routine effective
contraception remained, including worries about side effects, concerns about the commitment required,
ingrained stigma related to accessing sexual health clinics, and difficulties accessing repeat prescriptions
and appointments for continued contraceptive care. Such barriers are important to consider in wider
implementation of bridging as a service.
Conclusion
Provision of a bridging supply of the progestogen-only pill with emergency contraception from
a community pharmacist and the invitation to a sexual and reproductive health clinic result in a
significant increase in subsequent reported use of effective contraception. This simple intervention
has the potential to help prevent unintended pregnancies for women after emergency contraception.
As well as being acceptable to pharmacists, sexual and reproductive health providers and participants,
bridging as a practice seemed feasible in the pharmacy setting, despite existing contextual challenges.
This suggests that the practice could be widely implemented and routinely embedded in community
pharmacies, with some adaptations to alleviate challenges and recurrent barriers to long-term use
of effective contraception to encourage greater uptake. Suggestions to increase uptake of bridging
contraception in the pharmacy setting include greater advertising and promotion of the service,
provision of non-judgemental and supportive contraceptive consultations, an option to book routine
contraceptive consultations in pharmacies outside of emergency contraception consultations and
increasing the bridging contraceptive options available.
The findings of the mystery shopper study suggest that opportunities to provide emergency contraception
to women and to prevent unintended pregnancy are currently being missed in community pharmacies
across the UK. Lack of resources and changing priorities in the pharmacy and sexual and reproductive
health contexts highlight the need for sufficient resources and time to administer any enhanced emergency
contraception service and for it to be embedded in routine practice. Use of the rapid-access invitation to
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sexual and reproductive health services was limited and sexual and reproductive health services faced
challenges during the time of study, with funding cuts to services (London) that may have restricted access
to contraception for women. It is also possible that many women preferred to access contraception from
their general practitioner and that the perceived stigma of attending a sexual and reproductive health
service is still a barrier. The rapid-access invitation may be a less important component of the intervention
than the supply of the progestogen-only pill and therefore community pharmacies signposting to
contraceptive services may suffice.
The intervention tested in this study (i.e. a 3-month supply of the progestogen-only pill) should not
be a costly one, as the progestogen-only pill is an inexpensive drug, but this will be determined by a
cost-effectiveness analysis, which is under way but not yet completed.
The main limitation of this study is that the outcome was uptake of effective contraception rather
than unintended pregnancies. We had originally intended to examine abortion rates in each group as a
co-primary outcome, but during the study it became evident that we could not recruit sufficient numbers
of participants within a realistic time frame, and so we chose to focus on the uptake of effective
contraception. Use of effective contraception should prevent unintended pregnancy. Although participants
gave consent to allow subsequent data linkage with abortion registries, the sample size may be too
small to show any difference between the groups. Another consideration is that contraceptive use
was self-reported; however, there is evidence that women’s self-reporting of contraceptive method is
reliable. In addition, we had expected loss to follow-up in this study to be 25%, but it was larger at 35%,
although there was no difference in rates between the groups. Evaluation of the impact of the intervention
would be important following any future wide-scale implementation.
Trial registration
This trial is registered as ISRCTN70616901.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 27.
See the NIHR Journals Library website for further project information.
SCIENTIFIC SUMMARY




Unintended pregnancy is a major public health problem. Despite having one of the highest rates of
modern contraceptive use worldwide, the UK has among the highest abortion rates in Europe.1 In
2018, almost 200,000 pregnancies ended in induced abortion.2,3 Unintended pregnancy also ends in
childbirth. Around 10% of UK births are unintended and 25% are mistimed.4 Unintended pregnancy is
costly to the NHS5 and distressing for women. Unintended pregnancies are over-represented in young
women from deprived backgrounds. Unintended childbirth can have both socioeconomic consequences
for women and their families, and mental health consequences.6
Emergency contraception (EC) prevents pregnancy in individual women following unprotected sex
or contraceptive accidents (e.g. burst condom). Approval of EC from pharmacies and making it free
of charge to all women in Scotland and Wales, and free to many women in England, has increased
use and EC is now largely obtained from pharmacies.7 However, although trials have shown that
facilitating access to EC increases use of EC, these trials have failed to show an effect on unintended
pregnancy rates.8
Emergency contraception [containing levonorgestrel (LNG)] is only effective if taken within 72 hours
of unprotected sex. It does not prevent conceptions from subsequent sex. The risk of pregnancy is
increased up to threefold among women who have further unprotected sex in the same menstrual
cycle after using EC.9 An effective method of contraception should therefore be started as soon as
possible – known as ‘quick starting’.10 However, the only contraceptives available from pharmacies
without prescription are condoms, which have high failure rates.11 To start an effective contraceptive
(i.e. hormonal or intrauterine contraception) women must visit a general practitioner (GP) or attend a
sexual and reproductive health (SRH) clinic. It may take time to get an appointment and many women
may lose the motivation to seek contraception, leading to an unintended pregnancy. In addition, in
some UK studies, fewer than half of pharmacists gave advice about ongoing contraception after EC.12,13
There is a lack of evidence on interventions to increase uptake of effective contraception after EC.We
conducted a literature search of PubMed English-language articles from 2000 to March 2020 using search
terms (((bridging) OR bridge)) AND (emergency contracept*) and identified only two relevant articles. One
was a cluster randomised trial14 from Jamaica, in which women seeking EC were offered a voucher that
gave them a discount on the cost of contraceptive pills. This study reported no effect of the intervention
on subsequent contraceptive use. The other article15 was a pilot study of 12 pharmacies in Edinburgh,
with 168 women presenting for EC randomised to receive 1 month of a progestogen-only pill (POP), rapid
access to a local SRH clinic or standard care. Participants were contacted by telephone 6–8 weeks later to
determine which method of contraception they were using. In the POP arm, 35 out of 39 (90%) women
used the pills provided and 9 out of 28 (32%) women in the rapid-access arm attended the SRH clinic.
Compared with standard care, the proportion of women using effective contraception after EC was
statistically significantly greater in both the POP arm (56% vs. 16%; p = 0.001) and the rapid-access arm
(52% vs. 16%; p = 0.027). The study concluded that a 1-month supply of POP after EC or rapid access
to a SRH service might increase short-term uptake of effective contraception following EC, but that a
high-quality, adequately powered randomised trial was needed.
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Rationale for study
Unintended pregnancy remains a public health problem in the UK. Guidance from the Faculty of
Sexual and Reproductive Healthcare of the Royal College of the Obstetricians and Gynaecologists
(London, UK) stresses the need to ‘quick-start’ ongoing contraception after EC.10 In 2014, National
Institute for Health and Care Excellence guidance on contraceptive services for young people endorsed
this recommendation.16 In some parts of the UK, pharmacies are offering women supplies of contraceptive
pills after EC use,17 despite the lack of evidence that this is an effective intervention or is cost-effective.
We must show that the intervention is effective before we can recommend adoption of this approach.
A recent cost-effectiveness analysis of EC estimated that, in 2011, unintended pregnancies cost the NHS
over £1B.5 It is possible that even these costs are an underestimate of the ‘real costs’, as they did not
include the cost of managing medical complications of pregnancy or account for the additional costs
associated with teenage pregnancy. If a community pharmacy-based intervention could be designed that
was effective in reducing unintended pregnancies and was shown to be cost-effective, then this would
result in savings for the health systems, which could be invested elsewhere.Women who present for EC
should be given the best chance to prevent an unintended pregnancy.
Long-acting reversible contraception (LARC), which includes the implant, intrauterine contraception and
injectable contraception, has been shown to be the most effective reversible method of contraception
for preventing pregnancy.18 In recognition of the effectiveness of LARC, national initiatives in the UK to
increase uptake have been encouraged.16,18 Rapid referral of women using EC to SRH services capable
of initiating LARC immediately (as in this study) could do much to improve LARC uptake among women
at risk of unintended pregnancy.
We therefore conducted the ‘Bridge-It’ study: a robust trial to determine whether or not a pharmacy-
based intervention designed to facilitate the uptake of effective contraception after EC increases use
of effective contraceptive methods, compared with standard care alone. For the Bridge-it study, we
used a composite intervention of a small ‘bridging’ supply of the POP and the offer of rapid access to a
participating SRH clinic. This combined both temporary contraception (giving women time to arrange an
appointment with their usual contraceptive provider) with facilitated access to a specialist contraceptive
service (i.e. the SRH clinic) where all methods of contraception, including the most effective LARC
methods, are provided.
INTRODUCTION




The Bridge-it study was a pragmatic cluster randomised cohort crossover trial of community pharmacies
in three regions of the UK [London (south and central), Lothian (Edinburgh and region) and Tayside
(Dundee and region)].19 With this design, the order in which each community pharmacy provided
intervention or control was randomised. There was an intervening period of at least 2 weeks (during
which recruitment halted) before the pharmacy switched to the other recruitment phase.19 The cluster
design was chosen as our pilot study15 findings indicated that an individual randomised trial would not
recruit sufficient numbers of women. The crossover was chosen for efficiency, with each cluster acting
as its own control and fewer pharmacies required. The washout period between recruitment periods
minimised any contamination effect of pharmacists between recruitment periods.
Pharmacies were chosen to be a mixture of large commercial chain stores and small independent
stores. Each pharmacy had to have a sufficient volume of EC dispensing (at least 30 ECs per month)
to participate.
Women receiving LNG EC from a study pharmacy were considered for study participation. The LNG
EC was given in the appropriate dose (1.5 mg or 3 mg) for the woman’s weight.10
The intervention was a composite intervention. Women received 3 months worth of the POP (75 µg of
desogestrel/day) at no cost (as is the norm in the NHS) and the offer to attend a local participating
SRH service to discuss and provide ongoing effective contraception, including the most effective LARC
methods (i.e. intrauterine contraceptive methods and contraceptive implants).18 The three packets of
POP provide women with 3 months within which they could attend a contraceptive provider for
ongoing contraception. The POP has very few absolute contraindications,20 making it safer for pharmacy
provision than the combined oral contraceptive pill. The desogestrel POP was chosen as it is the market
leader, the most effective POP (as it has high rates of ovulation inhibition) and is inexpensive (£9 for
3 months of the generic version).21 Community pharmacists provided the POP using locally approved
patient group directions (PGDs) (i.e. strict criteria to permit provision of specified medicines by non-
prescribers).21,22 Participating pharmacists were trained on the study protocol and use of the PGD for
the POP, including information about medical contraindications to POP, potential drug interactions and
‘missed pill’ guidance. Pharmacists advised women to start the POP the day after the EC. Women in
the intervention group also received a rapid-access card that on presentation to the local SRH clinic
would help them to be seen as a walk-in patient to discuss contraception and obtain their preferred
ongoing method. The card provided information about the location of the SRH clinic and the opening
hours. The clinics (three in London, one in Lothian and two in Tayside) were located within 5 miles of
the community pharmacies.
In the control group, women received standard care with the EC (i.e. usual advice about ongoing
contraception). Mystery shopper visits with simulated patients12,13 were conducted in the pharmacies
just before recruitment started in the control group to document the content of the standard care EC
consultations (see Chapter 4).
Participants
Pharmacists assessed women’s eligibility for the study, invited them to participate, obtained written
informed consent for the study (including access to SRH clinic records and data linkage with the
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national abortion registries) and provided a patient information sheet. Participants completed a
baseline questionnaire that included demographic details, reproductive history and previous methods
of contraception used, including ECs (see Appendix 3). To maximise retention in the study, participants
received an online shopping voucher of £10 following recruitment.23
Procedures
Participants in both groups of the study had a single follow-up at 4 months: either a telephone interview
with a research nurse or a self-administered web-based questionnaire, according to participant preference
(see Appendices 4 and 5). In addition to contraceptive use, women were asked about their interaction
with the pharmacist and use of the rapid-access card (intervention group only). Participants reporting
pregnancy also completed the London Measure of Unplanned Pregnancy, which is a validated questionnaire
to measure the intendedness of the index pregnancy.24,25 Serious adverse events since recruitment were
also recorded.
The participating SRH clinics also searched their clinic record systems for data on if and for what
reason participants in both arms of the study had used their service during the 4 months following
recruitment.
Outcomes
The primary outcome was self-reported use of effective contraception (hormonal or intrauterine) at
4 months. Secondary outcomes were incidence of abortion in the 12 months following recruitment and
an economic evaluation of the intervention. Both secondary outcomes will be reported later [as per
agreement with the National Institute for Health Research (NIHR)].
A multimethod process evaluation was also conducted to assess implementation, mechanisms of
change and context,19 and included qualitative interviews with participants, pharmacists and staff at
SRH clinics. The process evaluation is reported separately in this report (see Chapter 5).
Sample size
An original power calculation for the study was based on two co-primary outcomes: (1) abortion rates at
12 months and (2) use of effective contraception at 4 months. For the abortion outcome, we required
> 2000 women to be randomised in at least 26 pharmacies to have 90% power at 2.5% level of significance
to detect a relative reduction of around 50. During the study, it became evident that recruiting this number
of women was not feasible within the available time frame and resources. The independent oversight
committees [the Trial Steering Committee (TSC) and Data Monitoring Committee (DMC)] and the funder
(NIHR Health Technology Assessment programme) agreed to repower the study on a single primary
outcome (i.e. use of effective contraception at 4 months). To have 90% power at a 5% level of significance
and to demonstrate an increase from around 30% to 45% (absolute change 15%, relative increase 50%),
the study required between 626 and 737 women, depending on the intraclass correlations (within period
and between periods), which were not observable within the study at the time this change was made.26
The sample size calculation assumed that we would not have the 4-month primary outcome data for
25% of participants and that there would be 25 participating pharmacies. For the intracluster correlations,
the within-cluster, within-period correlation was 0.032 and the between-period, within-cluster correlation
was also 0.032. The observed correlation between the two outcomes in the same cluster period compared
with the two outcomes from different periods in the same cluster was effectively zero (< 0.00001).
METHODS
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Randomisation
The order of delivery of intervention or control for each pharmacy was generated using a computer
software algorithm. This randomly allocated permuted blocks of size two, four and six, and blocking
was used to ensure a balanced order. The randomisation file was prepared by the study statistician at
the Centre for Healthcare Randomised Trials, University of Aberdeen (Aberdeen, UK), using SAS® 6.4
for Windows (SAS Institute Inc., Cary, NC, USA). Pharmacists were informed of the randomisation
allocation by the study trial manager. The study was not blinded.
Statistical analysis
Baseline characteristics of participants and 4-month follow-up data were summarised using mean
[standard deviation (SD)] or median (interquartile range) for continuous variables. Discrete variables
were summarised with numbers and percentages. The published study protocol19 specified a hierarchical
mixed-effects logistic regression on individual data for the analysis of reported use of effective contraception
at 4 months, and this represented our analysis intentions at the time of submission of the study protocol.
However, we revised this primary analysis in the final statistical analysis plan (accepted 5 November 2019,
before any unblinded data had been seen) to use a linear model on the unweighted proportion (expressed
as a percentage) at site level, following methodological guidance from Morgan et al.,27 and we used the
hierarchical mixed-effects logistic regression as a sensitivity-type analysis. Although the linear model on
percentages at site level makes less use of the available information, it can be more robust, with fewer
assumptions, and expresses the treatment effect as a percentage difference in proportion rather than as
an odds ratio.
Ideally, the design would generate equal contributions in each time period and each site would
contribute equal numbers. However, we knew from the aggregated accruing data on the database,
returned to date, that sites were quite different in size and also returning different numbers in each
period. Therefore, and guided by the Morgan et al.27 paper, which indicated that the simple approach
of modelling the percentages by site had the best properties in terms of control of type 1 error, we
took the unusual decision to prefer the simpler approach to the more complex hierarchical approach.
This resulted in forgoing the potential increase in power traded against the possibility of model
misspecification, as the model assumptions (regarding the several decompositions of within and
between cluster correlation, the influence of missing data, and the influence of very different sizes by
period and site) might have been violated. We felt that the hierarchical approach could still usefully
be reported as a sensitivity-type analysis and, as it happened, it does seem to support the simpler
analysis of proportions, giving similar estimates, but with the expected increase in precision.
For the primary outcome, the percentage of women reporting use of effective contraception in each
cluster period was analysed using linear regression, adjusting for period, treatment arm and centre,
and with centre as a fixed effect.27 Prespecified baseline covariates (i.e. mean age, percentage of
participants currently in a sexual relationship and percentage of participants who had previously used
effective contraceptive methods) were included as an additional analysis. A two-sided p-value < 0.05
was taken as statistically significant.
For the primary outcome, prespecified subgroup analysis for LARC use18 was performed using a stricter
level of statistical significance (two-sided 1% significance level) and 99% confidence intervals (CIs).
The sensitivities of treatment effect estimate to missing outcome data were undertaken using multiple
imputation. The missing primary outcome (i.e. uptake of effective contraception) was imputed using
all baseline characteristics as predictors, except for ‘previous ectopic pregnancy’ (because of small
numbers). Stata® version 16 (StataCorp LP, College Station, TX, USA) was used to impute 40 data sets.
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Summary of changes to the protocol
Owing to resource and time constraints, the study was repowered on a single primary outcome
(i.e. effective contraception use at 7 months). For the same reasons, the planned follow-up of participants
at 12 months was removed. Abortion rates at 12 months will still be collected and these and the cost-
effectiveness model will be reported separately (because of a later study end date than anticipated).
A summary of changes to the protocol can be found in Box 1. The final and previous versions of the
protocol can be found on the NIHR Journals Library [URL: www.journalslibrary.nihr.ac.uk/programmes/
hta/1511301/#/ (accessed 15 February 2021)].
Ethics
Ethics approval was obtained from South East Scotland Research Ethics Committee in June 2017.
Approvals were also obtained from NHS Research Scotland (Clydebank, UK) and Health Research
Authority (London, UK).
BOX 1 Summary of changes to protocol
Original submission to the Research Ethics Committee
Protocol version 1, 24 May 2017
Changes were requested to the exclusion criteria and how identifiable data would be handled. The protocol
was updated to version 2, 16 June 2017.
Approved.
Non-substantial amendment to protocol
Protocol version 3, 16 April 2018
There was a minor clarification to the wording on page 14 of the protocol to explain the time frame for the
two phases of the study:
Each pharmacy will recruit on average 80 women to provide around 60 evaluable women at 12 months.
30 women will be recruited to the intervention arm and 30 women will receive standard care. In order for
each pharmacy to recruit on average 80 women, pharmacies will recruit for approximately two months in
each intervention or standard care phase; some pharmacies will recruit for a shorter or longer duration
depending on the recruitment rate at the pharmacy and the size of the pharmacy. However, there will be a
minimum break (wash-out period) of two weeks in between the two recruitment periods.
Approved.
Substantial amendment to the protocol
In December 2018, a substantial amendment was submitted to the REC.
METHODS
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Protocol version 4, 12 November 2018
The primary and secondary end points were updated and the sample size was reduced to 626–737
participants. The trial team also requested a 6-month no-cost extension. The changes to the sample size and
extension were reviewed and approved by both the TSC and the trial funder (i.e. NIHR Health Technology
Assessment programme). The end date of the study was changed from 30 September 2019 to 31 March 2020.
Protocol version 5, 8 January 2019
The REC reviewed this in January 2019 and requested further changes to protocol to clarify at what time
GPs would be contacted.
Approved.
REC, Research Ethics Committee.
BOX 1 Summary of changes to protocol (continued)
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Parts of this chapter have been reproduced from Cameron et al.28 in accordance with the terms ofthe Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix,
adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
Recruitment and participant flow
Fifty-six pharmacies were approached to participate and 32 agreed to take part in the trial (Figure 1).
Twenty-nine out of the 32 pharmacies recruited participants (14 in London, 12 in Lothian and
Assessed for eligibility
(n = 56 pharmacies)
Randomised
(n = 32 pharmacies)
Recruited
(n = 29 pharmacies)
2-week washout phase
Did not recruit any participant, n = 3
Excluded
(n = 24 pharmacies)
Not eligible, n = 8
Declined to participate, n = 8
Did not respond, n = 8
Allocated to bridging contraception, n = 16
Received allocated intervention, n = 16
Average cluster size = 14.38, variance of
cluster sizes = 112.12
Allocated to standard treatment, n = 13
Received allocated intervention, n = 13
Average cluster size = 12.38, variance of
cluster sizes = 107.42
Allocated to bridging contraception, n = 13
Received allocated intervention, n = 11
Average cluster size = 7.82, variance of
cluster sizes = 67.76
Did not receive allocated intervention, n = 2
Reason: did not recruit
Allocated to standard treatment, n = 16
Received allocated intervention, n = 14
Average cluster size = 11.36, variance of
cluster sizes = 113.17
Did not receive allocated intervention, n = 2
Reason: did not recruit
Analysed, n = 21
Bridging contraception:
Average cluster size  = 13.86, variance of cluster sizes = 104.43
Standard treatment:
Average cluster size = 13.48, variance of cluster sizes = 119.96
Excluded from analysis, n = 8
Average cluster size = 7.50, variance of cluster sizes = 23.71
Reasons: did not have outcomes in one of the phases, n = 4;
                     did not recruit in one of the phases, n = 4
FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart.
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three in Tayside). Participants were recruited between 19 December 2017 and 26 June 2019. A total
of 1252 participants were screened, of whom 762 were eligible and 636 consented and were randomised.
Box 2 shows the inclusion and exclusion criteria.
Table 1 shows reasons for ineligibility and Figure 2 shows participant flow. The number of participants
recruited per pharmacy ranged from 2–35 in the pharmacies’ first recruitment period and from 0–38 in
the second period.
BOX 2 Inclusion and exclusion criteria
Inclusion criteria
Eligible for LNG EC confirmed.
Able to give informed consent to participate in and adhere to trial requirements.
Aged ≥ 16 years.
Willing to give contact details and be contacted at 4 months by telephone, SMS, e-mail or post.
Willing to give identifying data sufficient to allow data linkage with NHS registries.
Exclusion criteria
Contraindications to POPs.
Taking medication that interacts with POPs.
Already using hormonal contraception.
Requires interpreting services.
Pharmacist has concerns about non-consensual sex.
SMS, short message service.
TABLE 1 Reasons for ineligibility after screening (n= 490 women)
Reason n (%)
Does not require EC 93 (19.0)
Lacks capacity to give informed consent 64 (13.1)
Aged < 16 years 10 (2.0)
Unwilling to give contact details and be contacted for follow-up 264 (53.9)
Unwilling to give identifying data sufficient to allow data linkage with NHS registries 262 (53.5)
Contraindication to POPs 15 (3.1)
Medication that interacts with POPs 5 (1.0)
Already using hormonal contraception 156 (31.8)
Needs an interpreter 10 (2.0)
Pharmacist concerns about non-consensual sex 2 (0.4)
Note
Individuals may appear in more than one category.
RESULTS
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Table 2 summarises the baseline characteristics of participants by randomised group and recruitment
period. The mean age of participants was 22.7 (SD 5.7) years and 22.6 (SD 5.1) years in the intervention
and control groups, respectively. There were no statistically significant differences between groups.
Four-month follow-up
Follow-up data at 4 months were available for 198 out of 315 (62.9%) women and 208 out of 318 (65.4%)
women in the intervention and control groups, respectively. Follow-up rates did not differ statistically
between groups nor between those recruited in the first and second recruitment periods of pharmacies.
There were no substantial differences in any baseline characteristics between responders and
non-responders (Table 3). No significant adverse events were reported.




















FIGURE 2 Participant flow chart. n, number of women who returned a 4-month questionnaire; N, number of women
recruited; P, number of pharmacies.
TABLE 2 Characteristics of participants at recruitment
Baseline characteristic
Intervention Control
Period 1 (N= 229) Period 2 (N= 86) Period 1 (N= 161) Period 2 (N= 155)
Age (years), mean (SD) 23.2 (6.0) 21.4 (4.8) 22.2 (4.4) 22.9 (5.8)
Methods of contraception ever used, n (%)
Combined hormonal contraception 114 (49.8) 41 (47.7) 99 (61.5) 94 (59.9)
POP 39 (17.0) 19 (22.1) 35 (21.7) 32 (20.4)
Male condom 189 (82.5) 66 (76.7) 117 (72.7) 135 (86.0)
Progestogen-only injectable 14 (6.1) 6 (7.0) 10 (6.2) 18 (11.5)
Progestogen-only implant 29 (12.7) 10 (11.6) 23 (14.3) 19 (12.1)
Cu-IUD 6 (2.6) 0 4 (2.5) 4 (2.5)
LNG-IUS 0 1 (1.2) 4 (2.5) 2 (1.3)
Withdrawal method 65 (28.4) 28 (32.6) 52 (32.3) 67 (42.7)
Other methodsa 10 (4.4) 6 (7.0) 7 (4.3) 9 (5.7)
Never used any method 8 (3.5) 4 (4.7) 10 (6.2) 2 (1.3)
Past birth: yes, n (%) 30 (13.1) 5 (5.8) 7 (4.3) 13 (8.3)
Past termination: yes, n (%) 38 (16.6) 6 (7.0) 22 (13.7) 27 (17.2)
Past miscarriage: yes, n (%) 17 (7.4) 5 (5.8) 10 (6.2) 6 (3.8)
Current sexual relationship: yes, n (%) 176 (76.9) 55 (64.0) 104 (64.6) 111 (70.7)
First time ever use of EC: yes, n (%) 52 (22.7) 22 (25.6) 28 (17.4) 32 (20.4)
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TABLE 2 Characteristics of participants at recruitment (continued )
Baseline characteristic
Intervention Control
Period 1 (N= 229) Period 2 (N= 86) Period 1 (N= 161) Period 2 (N= 155)
Number of times used EC in the last 12 months
Mean (SD) 1.4 (1.4) 1.5 (1.5) 1.5 (1.2) 1.7 (2.0)
Median (25th, 75th centile) 1.0 (0.0, 2.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)
Minimum, maximum 0.0, 8.0 0.0, 9.0 0.0, 6.0 0.0, 20.0
Ethnic background, n (%)
White 157 (68.6) 60 (69.8) 98 (60.9) 114 (72.6)
Asian or Asian British 21 (9.2) 6 (7.0) 8 (5.0) 21 (13.4)
Black or black British 29 (12.7) 12 (14.0) 36 (22.4) 15 (9.6)
Mixed or other 19 (8.3) 6 (7.0) 17 (10.6) 6 (3.8)
Missing 3 (1.3) 2 (2.3) 2 (1.2) 1 (0.6)
Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.
a Other methods of protection included female condom, cap/diaphragm, vasectomy and natural family planning.
Note
Previous history of ectopic pregnancy was < 1% in all groups.
TABLE 3 Characteristics (at baseline) of responders and non-responders at follow-up
Characteristic (at baseline) Non-responders (N= 227) Responders (N= 406)
Age (years), mean (SD) 22.3 (5.0) 22.8 (5.7)
Methods of contraception ever used, n (%)
Combined hormonal contraception 118 (52.0) 230 (56.7)
POP 46 (20.3) 79 (19.5)
Male condom 157 (69.2) 350 (86.2)
Progestogen-only injectable 19 (8.4) 29 (7.1)
Progestogen-only implant 29 (12.8) 52 (12.8)
Cu-IUD 3 (1.3) 11 (2.7)
LNG-IUS 2 (0.9) 5 (1.2)
Female condom 0 3 (0.7)
Cap/diaphragm 0 6 (1.5)
Vasectomy 1 (0.4) 3 (0.7)
Withdrawal method 62 (27.3) 150 (36.9)
Natural family planning 7 (3.1) 13 (3.2)
Other method 1 (0.4) 2 (0.5)
Never used any method 11 (4.8) 13 (3.2)
Past birth: yes, n (%) 16 (7.0) 39 (9.6)
Past abortion: yes, n (%) 36 (15.9) 57 (14.0)
Past miscarriage: yes, n (%) 16 (7.0) 22 (5.4)
Current sexual relationship: yes, n (%) 154 (67.8) 292 (71.9)
First time ever use of EC: yes, n (%) 44 (19.4) 90 (22.2)
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Primary outcome: effective contraception use at 4 months
The proportion of women using effective contraception (hormonal and intrauterine contraception) was
20.1% greater (95% CI 5.2% to 35.0%) in the intervention group (58.4%, SD 21.6) than in the control
group (40.5%, SD 23.8) (adjusted for recruitment period, treatment arm and centre; p = 0.011) (Table 4).
Use of effective contraception remained statistically significantly higher in the intervention group
when adjusted for recruitment period, treatment group, study centre, age, whether or not currently in
a sexual relationship and history of past use of effective contraception, and was robust to the missing
data (Tables 4–6) using a multiple imputation approach under an assumption of missing at random.
Contraceptive use and long-acting reversible contraception use at 4 months
The methods of contraception used at 4 months after EC are shown in Table 7. The most common
methods used were oral contraceptive pills (POPs in the intervention group and the combined hormonal
contraceptive pills in the control group). There were no sterilisations or women relying on vasectomy.
Use of LARC methods (e.g. implant, intrauterine and injectable) did not differ between the intervention
group (13/198, 6.6%) and control group (23/208, 11.1%) (95% CI –10.04% to 1.05%; p = 0.112).
The most common reason given by respondents for not using effective contraception at 4 months was
that they were not currently sexually active (Table 8). Significantly fewer women in the intervention
group than in the control group had used EC again since recruitment [20/198 (10.1%) vs. 37/208
(17.8%)] (95% CI –15.38% to –1.48%; p = 0.018) (see Table 8).
TABLE 3 Characteristics (at baseline) of responders and non-responders at follow-up (continued )
Characteristic (at baseline) Non-responders (N= 227) Responders (N= 406)
Number of times used EC in the last 12 months
Mean (SD) 1.5 (1.2) 1.5 (1.7)
Median (25th, 75th centile) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)
Minimum, maximum 0.0, 6.0 0.0, 20.0
Ethnic background, n (%)
White 134 (59.0) 295 (72.7)
Asian or Asian British 25 (11.0) 31 (7.6)
Black or black British 42 (18.5) 50 (12.3)
Mixed or other 23 (10.1) 25 (6.2)
Missing 3 (1.3) 5 (1.2)
Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.





mean (SD) Estimate 95% CI p-value
Primary outcomea 21; 58.4 (21.6) 21; 40.5 (23.8) 20.1 5.2 to 35.0 0.011
Primary outcome adjustedb 21; 58.4 (21.6) 21; 40.5 (23.8) 14.5 0.9 to 28.2 0.038
a Adjusted for recruitment period, treatment arm and centre.
b Adjusted for recruitment period, treatment arm, centre, mean age, current sexual relationship and history of
effective contraception use.
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TABLE 6 Sensitivity analysis for hierarchical models [outcome= use of effective contraception (binary)]
Analysisa Intervention, n/N (%) Control, n/N (%) OR 95% CI p-value
Fixed effects for cluster 112/198 (56.6) 85/208 (40.9) 1.93 1.21 to 3.09 0.006
OR, odds ratio.
a Adjusted for recruitment period, treatment arm and centre.





mean (SD) Estimate 95% CI p-value
Omit cluster with fewer than three responses 14; 60.2 (19.7) 14; 42.9 (13.8) 15.2 2.3 to 28.1 0.026
Omit cluster with > 30% individuals with
missing data (excluded centre from the model)
5; 58.5 (14.4) 5; 44.1 (6.6) 14.7 1.1 to 28.2 0.040
Including percentage missing and number of
responders in the model
21; 58.4 (21.6) 21; 40.5 (23.8) 15.3 –0.1 to 30.6 0.051
Including percentage missing in the model 21; 58.4 (21.6) 21; 40.5 (23.8) 15.0 0.3 to 29.7 0.046
Including number of responders in the model 21; 58.4 (21.6) 21; 40.5 (23.8) 15.0 0.6 to 29.4 0.042
Multiple imputation 15.0 –2.0 to 32.0 0.076
a All analyses were adjusted for recruitment period, treatment arm, centre, mean age, current sexual relationship and
history of effective contraception use.
TABLE 7 Contraceptive use at the 4-month follow-up
Variable Intervention (N= 198), n/N (%) Control (N= 208), n/N (%)
Methods of contraception used nowa
Combined hormonal contraception 28/198 (14.1) 47/208 (22.6)
POP 71/198 (35.9) 15/208 (7.2)
Male condom 31/198 (15.7) 63/208 (30.3)
Progestogen-only injectable 4/198 (2.0) 4/208 (1.9)
Progestogen-only implant 3/198 (1.5) 11/208 (5.3)
Cu-IUD 3/198 (1.5) 4/208 (1.9)
LNG-IUS 3/198 (1.5) 4/208 (1.9)
Other method 0 1/208 (0.5)
Not using any method 57/198 (28.8) 62/208 (29.8)
LARCb 13/198 (6.5) 23/208 (11.1)
When did they start using this method?
Same day as EC 18/141 (12.8) 14/146 (9.6)
Day after EC 38/141 (27.0) 7/146 (4.8)
With start of period after EC 13/141 (9.2) 23/146 (15.8)
Other 48/141 (34.0) 62/146 (42.5)
Missing 24/141 (17.0) 40/146 (27.4)
RESULTS
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A significantly larger proportion of women in the intervention group reported that the pharmacist had
advised them about starting ongoing contraception (98% vs. 75.5%; p < 0.001) (Table 9).
A total of 158 out of 198 (79.8%) respondents in the intervention group reported that they used some
of the study POP that the pharmacist provided. Table 10 provides data on when women started the
POP, the number of packets of POPs used and reasons for non-use or discontinuation of the POP.
TABLE 7 Contraceptive use at the 4-month follow-up (continued )
Variable Intervention (N= 198), n/N (%) Control (N= 208), n/N (%)
Where did they get contraception from?
GP clinic 74/141 (52.5) 53/146 (36.3)
SRH clinic 34/141 (24.1) 35/146 (24.0)
Other 21/141 (14.9) 40/146 (27.4)
Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.
a Participants could use more than one method.
b LARC includes Cu-IUD, LNG-IUS, progestogen-only implant and injectable.
TABLE 8 Reasons for non-use of effective contraception at 4 months
Reasons for not using effective contraception Intervention (N= 57), n/N (%) Control (N= 62), n/N (%)
Not currently sexually active 27/57 (47.4) 28/62 (45.2)
Worried about side effects with contraception 12/57 (21.1) 21/62 (33.9)
Medical reasons 1/57 (1.8) 2/62 (3.2)
Not decided on method to be used 9/57 (15.8) 11/62 (17.7)
Difficult to get appointment 8/57 (14.0) 4/62 (6.5)
Difficult to find time to get to GP or SRH clinic 6/57 (10.5) 4/62 (6.5)
Trying for baby 1/57 (1.8) 0
Other 8/57 (14.0) 5/62 (8.1)
Further use of EC: yes 20/198 (10.1) 37/208 (17.8)
TABLE 9 Provision of contraceptive advice by community pharmacist
Contraceptive advice Intervention (N= 198), n (%) Control (N= 208), n (%) Effect size
Did pharmacist provide information about starting contraception?
No 2 (1.0) 46 (22.1) 0.216 (0.156 to 0.277); p < 0.001
Yes 194 (98.0) 157 (75.5)
Missing 2 (1.0) 5 (2.4)
Did pharmacist provide information about where to get contraception?
No 19 (9.6) 67 (32.2) 0.237 (0.159 to 0.315); p < 0.001
Yes 178 (89.9) 134 (64.4)
Missing 1 (0.5) 7 (3.4)
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TABLE 10 Use of POP by the intervention group
Use of POP Intervention (N= 198), n/N (%)





Not a regular partner 8/35 (22.9)
Not requiring regular contraception 7/35 (20.0)
Worried regarding side effects 10/35 (28.6)
Did not understand how to use it 1/35 (2.9)
Preferred another contraceptive 6/35 (17.1)
Used POP in the past and it did not agree 1/35 (2.9)
Preferred to see GP for contraception 2/35 (5.7)
Other 10/35 (28.6)
When did they start POPs?
Same day as EC 27/158 (17.1)
Day after EC 93/158 (58.9)
With start of period after EC 19/158 (12.0)
Other 16/158 (10.1)
Missing 3/158 (1.9)
Number of packets of POPs used
Less than one 15/158 (9.5)
One 17/158 (10.8)
Less than two 13/158 (8.2)
Two 8/158 (5.1)
Less than three 10/158 (6.3)
Three 70/158 (44.3)
Still taking POP 22/158 (13.9)
Missing 3/158 (1.9)
Main reason for stopping POPs before the supply ran out
Side effects 40/158 (25.3)
Started another method 6/158 (3.8)
Other 22/158 (13.9)
Missing 90/158 (57.0)
a Participants could tick all options that apply.
RESULTS
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Rapid-access card and sexual and reproductive health clinic utilisation
At the 4-month follow-up interview, 137 out of 198 (69.2%) respondents in the intervention group could
recall receiving the rapid-access card, but only 31 respondents (15.6%) reported that they attended the
SRH clinic. Only two respondents used the rapid-access card within 1 month of recruitment. Four out of
31 respondents (12.9%) received a LARC method at the SRH clinic (Table 11).
Data obtained from the SRH clinic databases showed that similar proportions of participants in both
the intervention and control groups actually attended the SRH clinics within 4 months of recruitment
[52/305 (17%) intervention group vs. 43/309 (13.9%) control group, 95% CI –2.60% to 8.87%; p = 0.284].
A total of 41 out of 95 (43.1%) attendees received contraception and the methods supplied are shown
in Table 12. There was no statistically significant difference in LARC provision to women in each group.
A total of 75 women both attended the SRH clinic and provided data at the 4-month interview.
For 34 of these women, the SRH clinic provided a contraceptive method. Thirty out of 34 (88%) women
reported using the same method of contraception at 4 months as the method provided by the SRH clinic.
Pregnancies in the 4 months since emergency contraception
Nineteen respondents (4.7%) (intervention, n = 9; control, n = 10) reported that they had been
pregnant (n = 17) or were currently pregnant (n = 2). The outcome of the pregnancies that had ended
were abortion in 10 women (58.8%) and miscarriage in six women (35.3%); this information was
unknown for one woman (5.9%). Based on the London Measure of Unintended Pregnancy24,25 scores
from the questionnaire, 15 out of 19 pregnancies (78.9%) had been unintended (seven in the intervention
group and eight in the control group).
TABLE 11 Uptake of rapid access to the SRH clinic
Variable Period 1 (N= 147), n/N (%) Period 2 (N= 51), n/N (%)
Did pharmacist provide a rapid-access card?
Yes 105/147 (71.4) 32/51 (62.7)
No 25/147 (17.0) 5/51 (9.8)
I cannot remember 12/147 (8.2) 12/51 (23.5)
Missing 5/147 (3.4) 2/51 (3.9)
Did they attend the SRH clinic?
Yes 25/117 (21.4) 6/44 (13.6)
No 90/117 (76.9) 35/44 (79.5)
Missing 2/117 (1.7) 3/44 (6.8)
If no, why?a
Not requiring contraception 19/90 (21.1) 9/35 (25.7)
Preferred to see a GP for contraception 45/90 (50.0) 17/35 (48.6)
Preferred to attend another SRH clinic for
contraception
5/90 (5.6) 0
Other 22/90 (24.4) 8/35 (22.9)
continued
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TABLE 11 Uptake of rapid access to the SRH clinic (continued )
Variable Period 1 (N= 147), n/N (%) Period 2 (N= 51), n/N (%)
When did they attend the SRH clinic?
Same day as EC 1/25 (4.0) 0
< 1 month after EC 1/25 (4.0) 0
1–2 months after EC 2/25 (8.0) 1/6 (16.7)
2–3 months after EC 12/25 (48.0) 3/6 (50.0)
3–4 months after EC 4/25 (16.0) 1/6 (16.7)
Other 4/25 (16.0) 0
Missing 1/25 (4.0) 1/6 (16.7)
Did they remember to take rapid-access card to the SRH clinic?
Yes 14/25 (56.0) 3/6 (50.0)
No 11/25 (44.0) 2/6 (33.3)
Missing 0 1/6 (16.7)
If no rapid-access card, were they refused an appointment?
Yes 1/11 (9.1) 0
No 10/11 (90.9) 2/2 (100.0)
How long did they wait at the SRH clinic?
< 30 minutes 8/25 (32.0) 3/6 (50.0)
< 1 hour 7/25 (28.0) 1/6 (16.7)
1–2 hours 8/25 (32.0) 1/6 (16.7)
Other 2/25 (8.0) 0
Missing 0 1/6 (16.7)
Did the SRH clinic provide a method of contraception?
Yes 19/25 (76.0) 5/6 (83.3)
No 6/25 (24.0) 0
Missing 0 1/6 (16.7)
Did the SRH clinic provide the participant’s preferred method?
Yes 16/25 (64.0) 5/6 (83.3)
No 8/25 (32.0) 0
Missing 1/25 (4.0) 1/6 (16.7)
If no, why?a
Not enough staff or time 2/8 (25.0) 0
Risk of pregnancy 1/8 (12.5) 0
Other 6/8 (75.0) 0
Method of contraception received
Progestogen-only implant 1/25 (4.0) 0
Progestogen-only injectable 0 0
Cu-IUD 1/25 (4.0) 0
LNG-IUS 2/25 (8.0) 1/6 (16.7)
RESULTS
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TABLE 11 Uptake of rapid access to the SRH clinic (continued )
Variable Period 1 (N= 147), n/N (%) Period 2 (N= 51), n/N (%)
Combined hormonal contraception 3/25 (12.0) 0
POP 12/25 (48.0) 4/6 (66.7)
Male condom 2/25 (8.0) 0
Experience of the rapid access to study SRH clinic
Smooth 16/25 (64.0) 3/6 (50.0)
Neither/nor 6/25 (24.0) 2/6 (33.3)
Problematic 1/25 (4.0) 0
Missing 2/25 (8.0) 1/6 (16.7)
Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.
a Participants could tick all options that apply.
Note
LARC includes Cu-IUD, LNG-IUS, and progestogen-only implant and injectable.
TABLE 12 Data from the SRH clinic databases
Variable
Intervention (N= 305),
n/N (%) Control (N= 309), n/N (%)
Attended the SRH clinic?
No 253/305 (83.0) 266/309 (86.1)
Yes 52/305 (17.0) 43/309 (13.9)
Method of contraception provided at this visit?
Yes 26/52 (50.0) 15/43 (34.9)
Method provided
Progestogen-only implant 2/26 (7.7) 3/15 (20.0)
Cu-IUD 1/26 (3.8) 4/15 (26.7)
LNG-IUS 1/26 (3.8) 3/15 (20.0)
Progestogen-only injectable 0 0
Combined hormonal contraception 3/26 (11.5) 1/15 (6.7)
POP 16/26 (61.5) 2/15 (13.3)
Male condom 3/26 (11.5) 3/15 (20.0)
Other method 1/26 (3.8) 0
Cu-IUD, copper-bearing intrauterine device; LNG-IUS, levonorgestrel-releasing intrauterine system.
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Chapter 4 Mystery shopper exercise
Parts of this chapter have been reproduced from Glasier et al.13 in accordance with the terms ofthe Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix,
adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
Mystery shopper exercise
Pharmacists were advised that one or two mystery shopper visits would take place before the control
group of the study started, but they were not told when these would occur. Visits took place between
April 2018 and January 2019. Research nurses recruited female volunteers (aged ≥ 16 years) to be
mystery shoppers and instructed them on the aims of the exercise, the scenario to be followed and the
data to be collected. The members of the patient and public involvement (PPI) group for the study
assisted in identifying potential mystery shoppers. The shoppers received £20 for each completed visit.
They followed a scenario (a single episode of unprotected sex within 72 hours) relating to a request for
EC. The scenario had been approved by the PPI group. Immediately after leaving the pharmacy, shoppers
completed a data collection pro forma, recording the time of arriving and leaving the pharmacy, duration
of the consultation and where the consultation about EC took place. They also noted any information
provided by the pharmacist, including advice on ongoing contraception. Data from the proforma were
entered into an Microsoft Excel® (Microsoft Corporation, Redmond,WA, USA) database and descriptive
statistics were conducted for each question.
Results
A total of 55 mystery shopper visits were conducted at the 30 study pharmacies participating in this
part of the trial. The mean total time reported spent in the pharmacy was 12 (range 1–47) minutes.
The median reported duration of the consultation with the pharmacist was 6 (range 1–18) minutes.
Consultations took place in a private room with 34 women (62%) and the remaining consultations took
place at the counter.
Eleven mystery shoppers (20%) were unable to get EC from the pharmacy. Seven mystery shoppers
reported that they were told that no trained pharmacist was available to provide EC. Four mystery
shoppers were told that EC was not in stock. Two of the latter women were aged 16 years and visited
the same pharmacy on the same day and both were advised to return 90 minutes later. A further two
mystery shoppers were advised that a copper intrauterine device would be more effective and were
directed to a SRH clinic for insertion, but neither was offered oral EC as an interim measure. Eight
mystery shoppers were told that they had to swallow the EC tablets in the pharmacy and seven
mystery shoppers (in London) were told that the pharmacy could not offer free EC. Three mystery
shoppers were asked to provide proof of identity and age to get free EC. Table 13 shows the results
for information provided by the pharmacist around EC or ongoing contraception.
A total of 27 out of 55 (49%) mystery shoppers received advice (oral or written) about ongoing contraception.
Forty-eight of the mystery shoppers made comments about their experience. Analysis of the free-text
comments showed four common themes: (1) the manner of the pharmacist, (2) being requested to take
the EC on the premises, (3) pharmacy not able to provide EC and (4) concerns about privacy. Examples
are shown in Box 3.
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Discussion
The mystery shopper exercise was undertaken to describe ‘standard care’ for the control group regarding
the request for EC at a community pharmacy. The exercise showed that, although pharmacists were
generally helpful, getting EC (for which all of the women were eligible) was not always easy (1/5 did not
get EC). In addition, waiting times were sometimes long, consultations short and privacy was not always
guaranteed. In a few cases, women were asked for proof of identity/age, which was not a requirement
of the local PGD in place for supplying EC. In addition, fewer than half of pharmacists in the mystery
shopper exercise gave any advice about ongoing contraception. These findings are similar to a previous
mystery shopper study from Edinburgh, published 10 years ago.12 Although the current mystery shopper
exercise was conducted in only 30 UK pharmacies and may therefore not be fully representative of care
across the UK, all participating pharmacists had recently undergone training for the Bridge-it study and
so one might have expected that the performance of these pharmacies regarding advice around ongoing
contraception would have been higher.
These findings suggest that opportunities to provide EC to women and to prevent unintended pregnancy
are currently being missed in community pharmacies across the UK. Furthermore, opportunities for
pharmacists to discuss ongoing contraception with women provided with EC are also being missed.
This adds to the debate of whether or not EC should be available on the general sales list (i.e. available
without the need for a consultation and purchasable from a range of outlets). According to the Medicines
and Healthcare products Regulatory Agency (London, UK), the general sales list is appropriate for medicines
that can, with reasonable safety, be sold or supplied in ways other than by or under the supervision
BOX 3 Free-text comments from mystery shoppers
He did however request for me to take the pill in front of him to make sure it is for me and not someone else.
He said this is required legally. I then stated that I am uncomfortable with it, apologised for any inconvenience
and left the pharmacy.
Mystery shopper B
They made me wait for a while and then fill out a form, which they kept. I was then told that they only had
one EC pill and they needed to give me two because the law had changed so I should go elsewhere. I don’t
think I spoke to a pharmacist at all, just a man who worked there?
Mystery shopper C
Initially asked at counter and the lady said to wait for the pharmacist. Had to repeat to pharmacist that
I needed EC. Quite a few people around.
Mystery shopper D
TABLE 13 Information provided by community pharmacist
Information provided or discussed Yes (n) No (n) Not completed (n)
Reason for needing EC 43 12
Information about accessing ongoing contraception 30 25
Oral information on importance of ongoing contraception 27 27 1
Oral advice to conduct a pregnancy test in 3 weeks 22 32 1
Written information on importance of ongoing contraception 5 50
Written advice to conduct a pregnancy test in 3 weeks 2 53
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of a pharmacist.29 The term ‘with reasonable safety’ has been defined as ‘where the hazard to health, the
risk of misuse, or the need to take special precautions in handling is small and where wider sale would be a
convenience to the purchaser’ (contains public sector information licensed under the Open Government
Licence v3.0. URL: https://nationalarchives.gov.uk/doc/open-government-licence/version/3/).29
It is now more than 20 years since EC was first approved as a pharmacy medicine in the UK.7 There is
abundant evidence to demonstrate that it does not present a hazard to health, nor is it widely misused,
and does not need special precautions. If ECs were a general sales list medicine, then there would be
more opportunities to obtain it, which would benefit women and, possibly, public health.
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Chapter 5 Process evaluation
The Bridge-it study included a multimethod process evaluation to assess implementation, mechanismsof change and context to better understand the effectiveness of the trial (see Table 14). This chapter
will report the methods employed and key findings relating to the following:
l Implementation – was the intervention implemented as planned?
l Mechanisms of change – how did the delivered intervention produce change in and impact on
contraceptive practices?
l Context – how did the local and broader context affect implementation and outcomes?
Findings are common across trial sites, unless indicated otherwise. Throughout the chapter, we
highlight those findings that are pertinent to future implementation of POP provision with EC.
Methods: data sources and analysis
We employed a range of quantitative and qualitative methods, including qualitative interviews with
providers (pharmacists and SRH staff) and participants, monitoring of pharmacy selection and training
observations, analysis of relevant data from the 4-month follow-up questionnaire and monitoring of
contemporaneous events (e.g. relevant media coverage). Further details on each data collection method
and analysis approach are provided in Appendix 1, Table 16. Collection of such data allowed us to
assess the role of our critical assumptions, mediators of change and intermediate outcomes that could
impact on the effectiveness of the intervention.
All process data were analysed independently from the outcome data and documented before the
outcomes were known. The process evaluation team (SP and LMcD) discussed the progress of
data collection and analysis on a regular basis, allowing any issues that were encountered to be
resolved (Table 14).
Qualitative interviews with pharmacists, sexual and reproductive health providers and participants
Qualitative interviews were conducted with those responsible for delivering the study (i.e. pharmacists
and SRH providers) and those receiving the intervention (i.e. Bridge-it Study participants). The breakdown
of recruitment by site is detailed in Figure 3. Specific details about sampling, recruitment, topics covered
and analysis for each group is detailed below.
Semistructured qualitative telephone interviews were conducted with pharmacists and SRH providers
to explore the acceptability of the intervention and training received (pharmacists), the perceptions of
barriers to and facilitators of implementation, and existing contextual challenges within their services
(see Appendix 2). In total, 22 pharmacists were interviewed (12 from Lothian, three from Tayside and
seven from London-based pharmacies). The aim had been to interview one pharmacist from each
participating pharmacy in the study. The main pharmacies not represented (n = 7) are based in London
(south), as it had not been possible to conduct interviews before the study was discontinued. Interviews
were conducted between July 2018 and July 2019, with most interviews taking place once recruitment
had ended in their pharmacy.
As well as interviewing pharmacists involved in the study, we interviewed five SRH providers in three
out of four participating NHS sites (two in Lothian, two in Tayside and one in London) between May
and October 2019. Our original aim had been to interview three or four staff members from each
service; however, recruitment was challenging, particularly because of low Bridge-it study participant
attendance at SRH clinics. Interviews were conducted 4–6 months after study recruitment had ended
to allow time for SRH staff to have experience of participants attending their service.
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Qualitative interviews were also conducted with a purposive sample of 36 intervention participants
(24 participants in Lothian, nine participants in London and three participants in Tayside) to explore
intervention acceptability, experiences of bridging from EC to effective contraception, facilitators of
and barriers to continued uptake and the wider context of their contraceptive experiences. Unintended
consequences were documented through the process evaluation, including asking participants whether
or not they perceived any unintended negative outcomes resulting from participation in the trial. Research
nurses asked participants for consent to be contacted by the process evaluation research assistant for a
qualitative interview at the end of the 4-month follow-up questionnaire, and interviews were conducted
between November 2018 and October 2019. Purposive sampling was employed to recruit a representative
and diverse sample, with participants sampled by area, age, use of the study POP and attendance at a SRH
clinic. The characteristics of the participants who were interviewed are shown in Table 15.
TABLE 14 The Bridge-it study process evaluation framework
Measure Questions to be answered Method/source
Implementation Fidelity:
l To what extent was the intervention delivered as
intended?
Acceptability and satisfaction:
l Do providers accept the intervention and adopt their
roles and responsibilities?
l Do providers understand their roles and responsibilities
clearly?
Participation and recruitment:




SRH providers and participants
Observation of pharmacist training
Monitoring and screening logs
Notes from TMG and TSC meetings
Mechanisms of
impact
Experiences of the intervention:
l What were participants’ experiences of the intervention?
l Did participants understand and implement the
intervention as intended?
Impacts on contraceptive knowledge and practices:
l How did the delivered intervention produce change?
l In practice, did the intervention address the
intermediate outcomes?
l Were the mediators of change identified as being
relevant to the intervention in practice?




pharmacists, SRH providers and
participants
Context How did the local and broader context affect
implementation and outcomes?
l What was the local context of the intervention
(e.g. pharmacy and SRH environment) relevant to its
implementation and outcomes?
l What was the broader context in which the intervention
was taking place (e.g. local/national policies that may
impact implementation; media coverage of reproductive
health issues)?
Qualitative interviews with




Notes from TMG and TSC meeting
TMG, Trial Management Group.
PROCESS EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
All provider and participant interview data were audio-recorded, transcribed verbatim and anonymised.
Data management was assisted by ethnographic software (NVivo 10, QSR International, Warrington, UK).
Transcription and analysis (proceeding case by case) began with the first interview and was ongoing during
data collection, allowing emergent themes to be identified and explored in future interviews. Data analysis
was undertaken using ‘framework analysis’, which is a method of proven validity and reliability in which
data are coded, indexed and charted systematically, then organised using a matrix or framework.30 Such a
method helps to ensure systematic thematic analysis and facilitates the synthesis of key themes across the
data set. Constant comparison was carried out to ensure that the analysis represents all perspectives and
negative (‘deviant’) cases.
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7 pharmacists 12 pharmacists 3 pharmacists






















In-depth telephone interviews with women, pharmacists
and SRH providers as part of process evaluation
FIGURE 3 Process evaluation flow chart.
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Monitoring of pharmacy selection and observations of training
To evaluate reach and recruitment, pharmacy selection was recorded using a standardised template
format. Study team members responsible for recruiting pharmacies routinely recorded decision-making
that contributed to pharmacy selection, including number of contacts made, responses from potential
pharmacies, rationales for inclusion/exclusion and reasons for acceptance/refusal.
To shed a light on intervention fidelity and delivery, and the potential impact of contextual factors, all
intervention and training materials were reviewed and observations of training sessions were conducted
by the process evaluation research assistant, where feasible. A standardised training observation form
was used to guide observations, with a particular focus on the way key processes of the intervention
were presented to and understood by pharmacists. In total, 13 training sessions were observed by
the process evaluation research assistant in Scotland. In London, the study trainers completed the
observation forms after each training session. Written observational data were transcribed into
Microsoft Word, thematic analysis was conducted and descriptive summaries were written.




















No service attended 13
Unknown 6




a Participants could attend both the GP and SRH clinic services.
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Monitoring of contemporaneous events
To monitor local, national and international contemporaneous events that could have an impact on
contraceptive use and behaviour over the course of the study, high-coverage media stories relating to
contraception were monitored and recorded over the study period (i.e. July 2017–December 2019).
Weekly Google Alerts (Google Inc., Mountain View, CA, USA) were set up using relevant search terms
(e.g. ‘contraception’ and ‘morning-after pill’) and key information was recorded in a Microsoft Excel
workbook (e.g. date of publication, news source, headline and topic focus). Relevance was assessed
primarily through the scale of coverage and source of publication. Articles were included if they were
published by a mainstream media source, such as widely read print/online titles (e.g. the Daily Mail,
the Guardian and the Metro), popular magazines (e.g. Time and Cosmopolitan), popular social media
news sources (e.g. HuffPost, LADbible and BuzzFeed) and other relevant and widely used internet
sources (e.g. BBC news website, Google News and Ofcom). Over the period of the study, 736 articles
were identified from mainstream media sources in the UK and were organised into key topic areas
(e.g. negative focus, personal stories, emerging contraceptive methods, accessibility of contraception,
contraceptive behaviour trends and general informative pieces). Descriptive summaries of key topics
identified and scale of coverage were created in Microsoft Word.
Quantitative data collected as part of the main study
Data from the pharmacist eligibility screening logs (n = 599) and relevant data from the 4-month
follow-up surveys (n = 406) were drawn on as part of the process evaluation to shed a further
light on acceptability, fidelity of implementation, barriers to participation and the uptake of routine
contraception. As part of the study, pharmacists were asked to screen all of those attending for EC
and to fill out a standardised screening form detailing reasons for ineligibility. Relevant data collected
from the 4-month follow-up survey included participation in the intervention (e.g. if the woman used
EC/POP, accessed a SRH service, started effective contraception, and if not then why not), delivery
of key mechanisms by pharmacists and SRH providers (e.g. information provided on where to access
further contraception, rapid-access card received and length of time at SRH service) and changes in
circumstances that could influence contraceptive use (e.g. change of partner or pregnancy). Data were
entered into statistical software package IBM SPSS Statistics and descriptive analysis conducted.
Researcher field notes and meeting minutes
Throughout the study, researcher field notes and reflections were documented, and meeting minutes
were analysed to record factors that may have influenced the consistency or quality of data, and
contextual factors that may have had an impact on implementation.
Synthesis of multiple data sources
After independent analysis of each data strand was completed, the findings from the multisource
process evaluation were integrated to shed a light on implementation, mechanisms of change and the
role of contextual factors on implementation and outcomes. To achieve this, key findings from each
stage of data collection were synthesised in an analytical integration table. The table was organised to
allow consideration of findings from each stage, with each strand being positioned in a single matrix
for each PE component (e.g. implementation, mechanisms and context) (see Appendix 1). This method
facilitated the systematic synthesis of the process data, drawing out synergistic interpretations to
reveal a broader holistic perspective on how the intervention worked in practice.
Implementation
Pharmacist and sexual and reproductive health provider acceptability of the intervention
The majority of pharmacists and SRH providers were very positive about the premise of the
intervention and the role of pharmacy in developing and improving contraceptive services.
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Bridging in community pharmacies was seen as an important way to improve access to contraception
and to reduce repeat EC use and unwanted pregnancies:
. . . it shows that people are taking the issue of unwanted pregnancy seriously and they’re trying to
improve, you know, the accessibility of services to women . . . and the choice that’s available to them.
Pharmacist 18, Lothian
As well as the pharmacy setting being viewed favourably, the EC consultation was seen as a particularly
suitable and opportune time to offer access to routine contraception:
I also think it’s quite an opportune time when somebody comes in for emergency contraception, to pick up
on, you know, sort of routine contraception. You know, the fact that they need emergency contraception,
obviously something has gone wrong, so it’s a good time to be able to kind of go, well actually, have you
had a think about this, or how can you deal with this kind of thing?
SRH worker 1, Lothian
It was suggested that approaching women in this way could break down some barriers (e.g. lack of
time, difficulties accessing contraceptive appointments and avoidance) to accessing routine
contraception at critical times.
Acceptability of taking part in a research study
Figure 4 shows the pharmacist support and training that was provided for delivering the Bridge-it study.
During training sessions, the majority of pharmacists seemed enthusiastic and motivated to take part in
the study and often reflected on this in interviews, expressing a desire to take part in more research:
I’m kind of like, I’d love to be involved in more things so I’m always welcome . . . you know, I’m welcome to
do more kind of projects like this.
Pharmacist 20, London
Central delivery of
training in a central
venue  
Small group training at
pharmacies, where this was
more achievable  
1. Overview of Bridge-it study
     slide presentation/discussion
2. Good clinical practice awareness:
     slide presentation
3. PGD discussion of requirements and
     how to raise the ongoing contraception
     issue
4. Bridge-it study database slide presentation
5. Completion of study documents,
     discussion and practical session








Implementation of Bridge-it study protocol
Recruitment of participants
FIGURE 4 A flow chart of pharmacist training and support for delivering the Bridge-it study.
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In particular, pharmacists who had been involved in the earlier pilot study15 or who had previous
experience of pharmacy-based interventions were particularly enthused and seemed to be more
accepting of the pharmacist role in the study, potentially because of familiarity with the kinds of
processes and documentation required for trials. It is important to note that pharmacists who were
particularly enthusiastic about the benefits of bridging through community pharmacies for patients,
and about taking part in the study, were those who tended to recruit the most participants, perhaps
highlighting the importance of ‘buy-in’ to the premise of the intervention.
Although most pharmacists reflected positively on the premise of the intervention and on taking part
in research to expand contraceptive services, some concerns were raised during training. Pharmacists’
concerns typically focused on worries relating to managing the additional time and workload pressures
of taking part in a research study (rather than of delivering POP per se), scepticism that additional time
would be set aside to accommodate this, and concerns about how the study would fit with existing
practices and changing guidelines relating to EC. These concerns are detailed in The impact of context
on the Bridge-it study implementation and outcomes and focus on facilitators of and barriers to delivery
and implementation in practice.
Pharmacist and sexual and reproductive health provider awareness of the
study and preparedness to deliver
Pharmacists’ perceptions of and satisfaction with training
Observation of training demonstrated fidelity across sites, with sessions typically delivered as per the
training guidance, covering all components and being consistent in content. Adaptations to training
typically related to the time spent on particular components, fuelled by contextual factors such as lack
of time. The majority of pharmacists were positive about the training received for the Bridge-it study
and described the study as ‘informative’, ‘concise’, ‘well-designed’ and ‘convenient’. Pharmacists typically
described being satisfied with the training staff:
. . . it was good, they were very clear, lovely manner the ladies had, so you didn’t feel daft asking a
number of questions . . .
Pharmacist 8, Tayside
The venue, composition and timing of training also seemed to be acceptable to the majority of
pharmacists, with different options available, small-group learning-facilitating dialogue and well-timed
training encouraging confidence:
I think it was good. It wasn’t a particularly large group of us doing it. I think there were about sort of
8–10 so we were able to ask questions and chat and things which was quite good .
Pharmacist 11, London
I think it worked really well, I could start it straight away and it would be fresh in my mind because the
training was a week before they would launch it, so it was good.
Pharmacist 2, Lothian
Pharmacists were also generally satisfied with the content of training and the study resources provided:
. . . the training was pretty good, pretty informative. And I think the material provided . . . stuff that they
provided for reading was pretty informative as well.
Pharmacist 18, Lothian
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The majority of pharmacists that were interviewed indicated that the training provided prepared them
to deliver the intervention as planned, but acknowledged that time and practice were necessary to be
fully prepared:
Obviously just with any of the new services it does take you just a . . . to get into a rhythm of like filling in
all the paperwork and things like that.
Pharmacist 6, Lothian
However, some ways in which the training could have been improved to bolster preparedness were
highlighted, including through drawing on pharmacists’ expertise in designing the training, increasing
practice-based and role-play learning, and providing formalised refresher training between phases.
Awareness in sexual and reproductive health centres
Sexual and reproductive health providers were made aware of the study through management in their
services. SRH providers interviewed described a lack of familiarity with their role in the study and a
general lack of awareness of the study in their service:
I’m aware of a lot of studies but I wasn’t really aware of this one too much. I never saw any of the signs.
You know? I never saw anything.
SRH provider 5, London
Most SRH providers indicated awareness of the study waning over time and stressed the need for
reminders and easy and accessible study information to be available for all staff (including front-line
reception staff).
Fidelity of intervention delivery
Experiences of delivery in participating pharmacies
Pharmacists’ descriptions of delivery and women’s accounts of their experiences in participating
pharmacies suggest that fidelity of delivery was, on the whole, achieved. Although pharmacists’
descriptions of the recruitment process suggested adherence to the training protocol, there was some
evidence of fatigue with research procedures, with failure to complete screening paperwork or enter
data into the database relatively common across sites. Therefore, the added burden of the research
context was apparent, typically extending EC consultations by approximately 15–20 minutes:
It’s a time-consuming process. So sometimes you need to manage your time really, really well and be very
tight with time to fit it all in.
Pharmacist 1, Lothian
Research nurses from all sites reported having to spend a substantial amount of effort on the ground
to encourage pharmacists to recruit and to assist with paperwork and database entry. Such experiences
suggest the need for a more streamlined process with less paperwork and repetition, and the need for
a high level of in-person support during implementation. However, the nurses noted that most of this
related to taking part in a research study rather than the provision of POP as a bridging method itself.
The impact of the pharmacy context on implementation is described in more detail in The impact of context
on the Bridge-it study implementation and outcomes.
Women typically discussed positive and informative experiences in participating pharmacies:
. . . the lady who gave me all the advice on it, she was really, really thorough at explaining everything.
She helped me out with the forms as well.
Participant 15, London
Data from the 4-month follow-up survey demonstrated that 90% (n = 178) of intervention participants
recalled being given information about accessing further contraception during the EC consultation,
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in contrast to 64% (n = 134) of control participants. Most of the participants interviewed recalled being
advised to access further contraception through either the participating SRH clinic (with rapid-access
card) or their GP, typified here by participant 1, Lothian:
. . . so he said that I could either go into the clinic, and he gave me one of the ticket things [rapid-access
card] to hand them [ . . . ] and he also said that if I told my GP about the study and what pill it was,
they’d be able to give it to me as well.
Therefore, participants’ accounts highlighted that information around further access to contraception
was predominantly accurate, consistent and clear, and may have contributed to many going on to
successfully access further contraception. It is important to note that most women accessed further
contraception through their GP (74/141) rather than a SRH clinic (21/141), and there was no
difference in the proportion of women in either the intervention group or the control group who
accessed the SRH service.
Although the majority of participants described being satisfied with the information provided in the
pharmacy context, some inconsistencies in information provision emerged. Some indicated that they
would have benefited from more in-depth information about the study and process involved:
I wouldn’t say from the initial chat with the pharmacist that I got a totally clear picture.
Participant 12, Lothian
It was not uncommon for participants to think that the aim of the study was to test out a new
contraceptive pill, rather than about increasing access to further routine contraception:
It would be because you’re testing out a new drug to give out at pharmacies and GPs [ . . . ] and there
was loads of girls getting asked to be part of the project to do statistics and see how it was affecting
certain people.
Participant 10, Lothian
This framing of the intervention and lack of understanding about the aim may have had an impact on
decision-making around accessing further contraception and motivations to do so. Around one-quarter
of intervention participants (n = 54) could not recall being given a rapid-access card, typified by
participant 35:
Interviewer: Do you remember if you were given a study card?
Participant 35, London: No, I don’t have a study card.
Interviewer: Were you told where to go if you had any issues with the contraception or if you wanted to
get more?
Participant 35: Yes, he said that I could go there [pharmacy] and get my card and then obviously keep
getting the pill but he wasn’t there when I last went so . . .
Such accounts highlight that there were some inconsistencies in information provided to participants
in participating pharmacies, which resulted in confusion and, in some cases, trouble accessing
further contraception.
Experiences within participating sexual and reproductive health clinics
As already highlighted, the SRH providers interviewed described a general lack of awareness of the
study in their services, and few SRH providers interviewed described encountering Bridge-it study
participants. In contrast to participants’ reflections on experiences in participating pharmacies, those
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who attended participating SRH clinics as part of the rapid-access component of the intervention
reported less positive experiences, with a general lack of awareness among SRH staff encountered:
I think I spoke to someone who didn’t know what I was talking about, because when I went over and
was like, can I have these . . . I was like, I’m with the study, can I please get some more contraceptive?
And I don’t think she really knew, she was like, oh make an appointment with your GP.
Participant 5, Lothian
Such an experience was not uncommon, with four out of the five interviewed participants who
attended their local SRH centre reporting difficulties accessing an appointment for further routine
contraception in this way. Two participants were unable to access rapid appointments because the
services were too busy. Although one participant overcame the time-related barriers and returned on
another day, another participant was asked to wait for 2–3 hours and was unable to, and thus failed to
access further contraception:
So waiting for 2 hours and being a working individual where clinics aren’t open 24 hours either, I just think,
you know, some things you just have to bite your tongue with. So to cut a long story short, I’m pregnant.
Participant 23, London
Barriers to recruitment
During the Bridge-it study period, recruitment was slow and initial recruitment targets were not met,
both for recruiting pharmacies and participants to take part in the study. This section describes the
challenges of recruiting pharmacies and explore barriers to participation in the study that may have
implications for wider implementation of bridging as a service in pharmacies.
Branches of large chain pharmacies and smaller independent pharmacies were approached to take part
in the study because of their proximity to the participating SRH services, large footfall and high EC
dispensing rates. Initially, it was decided to approach only those pharmacies with a dispensing rate of
> 30 ECs per month, which ruled out many of the smaller independent pharmacies that appeared to be
easier to set up. However, because of delays with setting up some of the larger chain pharmacies, the
pharmacy recruitment strategy was adapted (September 2017) to allow consideration of pharmacies
with lower EC dispensing rates. In total, 21 pharmacies that were initially approached were excluded
or refused to take part. Barriers to pharmacy selection and recruitment included low EC distribution,
charging for EC, already being commissioned to give out oral contraception after EC, lack of interest/
enthusiasm and pharmacy environment/workload (e.g. too busy, understaffed and other disruptions).
Barriers to participation
Analysis of screening log data and pharmacist accounts in interviews indicated a variety of barriers to
participation. In screening logs, pharmacists most commonly recorded unwillingness to give contact
details for follow-up (n = 264) or data linkage (n = 262); in qualitative interviews, pharmacists expanded
on these research-related barriers to participation, highlighting the time-consuming nature of paperwork
and worries relating to confidentiality of data:
. . . lots of them were concerned about confidentiality, they were scared that I could just share the data
with the GP.
Pharmacist 3, Lothian
Uncertainty around bridging as a new practice was also highlighted as a barrier to participation:
I mean, a lot of people were a little bit . . . they weren’t too sure about it I suppose, but they’re usually
going to their doctor, so there was maybe issues there that they were just a little bit uncertain about the
process of getting this through the pharmacy.
Pharmacist 5, Lothian
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It seemed that the unfamiliar nature of this practice acted as a deterrent to some. Some thought that
these particular barriers to participation would be overcome if bridging became an established
pharmacy service, with less paperwork and greater advertising and awareness of the service:
I mean, if it was more widely known and became a more accepted pharmacy service, you would see
more people.
Pharmacist 5, Lothian
Pharmacists talked about greater awareness resulting in more people participating, having time to
decide whether or not to participate and visiting pharmacies specifically for longer-term contraception.
As well as research-related barriers, pharmacists drew attention to some barriers to participation that may
impact on uptake if bridging were widely implemented as a service in this format, which therefore require
consideration. Narratives of resistance to take POP specifically or hormonal contraception generally were
commonly raised by pharmacists as a barrier to participation:
Interviewer: Do you think there’s anything that prevented people from participating?
Pharmacist 12, Lothian: Erm, well I’d say, the choice of it only being one pill, would definitely have been
one. A lot of people didn’t like the fact that it was the progestogen-only one.
As well as a lack of choice of contraceptive bridging options available, pharmacists commonly described
lack of time and a sense of rush as being common to EC consultations and a barrier to further discussion:
. . . the main problem is people are in a rush every time they come in to get the morning after pill.
Pharmacist 15, London
Pharmacists highlighted that this sense of rush often appeared to be due to busy schedules and limited
time, as well as, at times, embarrassment or a desire to move on from the event:
I expect, embarrassment, that they just wanted to come in and out, you know, we are talking about
something that people feel embarrassed about, they just want to come in, swallow the tablet, get out,
forget the whole thing ever happened.
Pharmacist 8, Tayside
Some pharmacists also indicated that potential participants may have been deterred by lack of time to
consider participation, particularly as decision-making around contraception often requires thoughtful
consideration. Therefore, the immediate need to make a decision, combined with embarassment, lack
of time and lack of choice, may have acted as barriers to participation in the study and could have
an impact on uptake if bridging were widely implemented as a service. Suggestions to alleviate such
barriers in wider implementation include provision of non-judgemental and supportive consultations,
flexibility regarding accessing routine contraceptive services (e.g. option to book appointment) and
increasing the number of contraception options available. In particular, the option of being able
to book appointments to discuss further routine contraception with their pharmacist without the
prerequisite of taking EC was favourable for many of those interviewed, making the service more
feasible in the pharmacy setting and more beneficial for patients. Some of these potential solutions
to increase uptake if bridging were widely implemented would be relatively straightforward to
implement (e.g. a continuing professional development course on supportive consultations), whereas
others would require practice or regulation changes. Box 4 provides a summary of key learning for
future implementation.
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Mechanisms of impact: participants’ experiences of bridging and impacts on
contraceptive practices
This section will focus on participants’ experiences of bridging and the impacts on contraceptive
practices in the short and, potentially, long term. The aim is to shed a light on potential mechanisms of
change and both facilitators of and barriers to uptake of bridging in future.
Mechanisms of change: access, knowledge, confidence and self-efficacy
Overcoming barriers to accessing regular contraception
Participants’ descriptions of their experiences suggest that bridging in the pharmacy context may
have a positive impact on contraceptive knowledge and practices, in both the short and, potentially,
the long term, overcoming both personal barriers (e.g. avoidance, lack of time) and structural barriers
(e.g. difficulties accessing appointments) to the uptake of routine contraception. It seemed that, for
many of the participants, being approached in the pharmacy setting when attending for EC provided
them with the ‘push’ they needed to prompt a change in their contraceptive practices:
I think it was good because I probably would’ve taken a lot longer to figure it out and how to get it
myself. And it was really convenient. It made me kind of realise that it was time to go on one and that it
was something I did need to do.
Participant 10, Lothian
This also highlights the EC consultation as an opportune moment to intervene, as indicated by
pharmacists and SRH providers, and how offering bridging could interrupt potential repeat EC use,
which is viewed as a persistent issue in some community-based pharmacies. As one participant highlighted:
It was just a huge bonus to me having something that meant I didn’t have to wait even longer, because
I probably inevitably would have . . . in that gap again, probably had to go for more emergency contraception.
Participant 18, Lothian
Participant accounts emphasised the importance of the pharmacy setting in overcoming existing access
barriers to contraception in traditional contraceptive health-care settings (e.g. general practices, SRH
clinics). Difficulties accessing routine contraception were commonly discussed in terms of finding the
time to access contraceptive services and GP appointments, as well as in relation to the availability
of services:
Interviewer: So what do you think makes it difficult to access effective contraception, so to have a
regular contraception?
BOX 4 Key learning for future implementation 1
l The intervention was acceptable to pharmacists and SRH providers and was seen as an important way
to develop and improve access to contraceptive services.
l A lack of awareness in SRH services emphasised the need for integration and regular communication
with all services involved in implementation and delivery.
l Fidelity of delivery was mostly achieved and highlighted the importance of clear and consistent
messaging around access to further contraception.
l Barriers to participation included research-related factors, as well as barriers relevant to wider
implementation as a service (e.g. embarrassment, lack of time and choice).
l Suggestions to overcome barriers to participation include greater choice of contraceptive bridging
methods, an option to book appointments in pharmacies and greater advertising of the service.
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Participant 8, London: I think, well, if you go to the GP or if you go to a [SRH] clinic, it’s just the waiting
time and you have to take quite a bit of your day up, to be honest. If you go via the GP, I have to book
my appointment two, three weeks in advance.
Participants in London seemed to struggle particularly, as one participant said:
To be honest, getting an appointment in London is actually the worst thing ever.
Participant 35, London
Participants highlighted the convenience and availability of pharmacies as pivotal in helping to
overcome such existing barriers to accessing contraception:
I know pharmacies are often open early or they’re open late and they’re open at lunch times so if I can go
then and I don’t have to book time out of work to go to a GP or a doctor that’s like 09.00 to 17.00, then
that would be great.
Participant 12, Lothian
As well as helping to overcome barriers of time and difficulties in accessing appointments, some
described how the pharmacy context could help to alleviate the potential embarrassment of accessing
contraception in more traditional ways, with many valuing the fact that pharmacy consultations tended
to take place in small private rooms and were typically discreet and non-judgemental:
I think every pharmacy has a little room for you to go in and it’s quite discreet.
Participant 19, Lothian
Therefore, key mechanisms of change that are specific to the pharmacy setting were those of access
and the nature of the setting, resulting in easier, convenient and potentially less embarrassing access
to contraception.
In practice, pharmacists highlighted the immediate positive impact of being able to offer bridging
contraception and the real need and demand for this service:
. . . there are a lot of people come in and ask about getting contraception and what you can and can’t
supply and things, so some sort of extended service would probably fit in well.
Pharmacist 5, Lothian
Specific populations, including young people and students, were mentioned as being particularly prone
to experiencing such difficulties and being appreciative of the service. Owing to the existence of
ingrained difficulties to accessing appointments in more traditional settings and the existing demand
for a more accessible service through pharmacies, pharmacists typically were optimistic about the
feasibility of changing behaviour through the study, highlighting a synergy between the intervention
design and patient need.
Increased knowledge, confidence and self-efficacy
As well as access being highlighted as a key mechanism of change, participants drew attention to a
variety of other potential benefits related to taking part in the Bridge-it study. These included
heightened awareness and knowledge of contraception and contraceptive services:
I found out more about it [contraception]. I’ve got more knowledge of that type of stuff now so that’s one
of the positive things, I guess.
Participant 9, London
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Some described how this increased awareness and knowledge of contraception and available services
improved their confidence in both accessing contraception and in relation to protecting themselves
from risk:
It’s meant that I’m on the pill, I’ve got that sorted, I know that I can go to the pharmacy to get advice,
I hopefully won’t be needing the emergency contraception again, but I know that I can get it there if, for
whatever reason, I need it. Yeah, I think, it’s probably given me a bit more confidence with it as well.
Participant 36, Tayside
It has definitely forced me to make me more aware, so I’ve not had unprotected sex since then. So yes
and obviously now I’m a lot more open to actually go ask about it and try and get on one.
Participant 7, Tayside
Such accounts highlight key potential mechanisms of change in the uptake of effective contraception,
with increased knowledge, confidence and self-efficacy possibly working to foster healthier practices
and attitudes towards sexual health and risk.
Pharmacists also discussed that, although the Bridge-it study might not always be successful in driving
uptake of hormonal contraceptives, the intervention likely prompted people to think more about their
sexual health and consider longer-term contraception, as typified here:
Interviewer: And what, if any, positive effects do you think the Bridge-it intervention had?
Pharmacist 17, Tayside: I think it had quite a lot, to be honest. A lot of people probably thinking more
about their sexual health, thinking more about longer-term contraception. A lot of them hadn’t maybe
thought about starting on contraception after taking EC, so when I was explaining the importance of that,
they were like, oh, you know, that’s quite a good thing to do . . . Even the people that maybe turned me
down I think it still had a positive impact on them because they’ll go away and maybe think about it now,
so I don’t think it was negative in any way.
This pharmacist also highlighted how further positive outcomes may be linking patients with local
sexual health clinics, raising awareness of availability of testing and other related services.
Facilitators of and barriers to continued uptake of routine contraception
It is important to explore why the intervention worked for some participants and not for others. As
indicated in the main outcome findings, over half (122/198) of the intervention participants remained on
effective contraception at the 4-month follow-up, with 36% (71/198) remaining on POP, 14% (28/198)
on the combined hormonal contraceptive pill/patch/ring and 7% (13/198) on LARC methods. However,
although many participants overcame barriers to continued uptake of effective contraception, 44%
(88/198) of intervention participants were not on contraception at the 4-month follow-up.
Why did participants remain on effective contraception?
Participants who remained on effective contraception typically found the process of accessing further
supplies through their GP or SRH clinic straightforward, and tended to have positive or no side effects
in response to taking POP:
I don’t feel that there has been any side effects, like, of like up and down moods or mood swings that
some other women get on different pills, which is very positive.
Participant 1, Lothian
I really like it, so I’ve actually went and got some more of that now [ . . . ] afterwards I just went to the
doctor and got some more because I don’t know, I like it.
Participant 17, Lothian
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Familiarity was also highlighted as a reason for continued use of oral contraception specifically:
At the moment I do feel happy on it and it’s convenient, I’m used to taking the pill, and my friends are
like, oh coil is so easy because you don’t have to think about it, but I’m used to it.
Participant 18, Lothian
A number of participants described considering changing to other options in the future. For example,
participant 16 indicated that she would like to try something more long term, but had concerns
relating to the implant insertion procedures:
The implant I’m a bit scared of because sort of like the injection stuff, I’m not a fan of that, but I would
want to because I think I’ve heard a lot of good stuff about it, so I’m not sure, yeah. Still debating it . . .
Participant 16, Lothian
Participant 16 later elaborated that she would also struggle to find the time to access an appointment to
discuss other options, stating ‘I’m just quite busy and I don’t have the time to go and get another one really’.
Some of the participants who remained on effective contraception post study were those who had no
prior experience of routine contraception. For example, participant 8 (London) described herself as a
frequent user of EC and highlighted barriers to accessing appointments as the primary reason for not
being on routine contraception prior to taking part in the Bridge-it study:
It was just the convenience of booking an appointment. Sometimes I have to wait 3 weeks or so and then
it all conflicts with my day-to-day life.
Participant 8, London
Such experiences highlight the beneficial nature of offering bridging in accessible settings such as
community pharmacies in overcoming existing barriers to accessing effective contraception. As well as
the Bridge-it study having an impact on previous non-users, bridging seemed to be beneficial for some
participants who had previous negative experiences on other forms of hormonal contraception. A
minority of participants who had previous particularly negative experiences with other hormonal
contraception also found the POP to be suitable:
And to be fair these . . . the pill that I’m taking just now has been great for me. And if that hadn’t
happened last year and nobody had talked to me about it, I don’t know if I would have ever tried it,
I would probably still be thinking that the pill is evil.
Participant 27, Lothian
This participant had almost lost hope in the pill as a suitable method of contraception because of
previous negative side effects from other oral contraception, but tried it after being approached to
take part in the study and, at the time of interview, had been satisfactorily using POP since then. Such
accounts highlight the barriers to accessing contraception, the sometimes time-consuming nature of
finding the right contraceptive, the importance of individuals being supported in their contraceptive
journeys and the benefits of offering bridging contraception through multiple routes, including
community pharmacies.
Barriers to continued uptake of effective contraception
The 4-month follow-up survey and interviews with participants shed a light on a range of barriers
to continued uptake of POP or to seeking alternatives, which are important to consider for future
implementation. For many, personal circumstances, such as not being sexually active, their current
relationship status or being pregnant, resulted in them deciding to not be on contraception. Data from
the 4-month follow-up survey indicated that almost half (28/57) of intervention respondents who were
not on effective contraception cited such circumstances.
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As well as personal circumstances, a range of other reasons were highlighted as barriers to continued
uptake of effective contraception. At follow-up, one-quarter (40/158) of respondents from the intervention
group discontinued POP before their supply had run out because of worries about side effects. Participants
who were interviewed described a range of adverse side effects they attributed to taking POP, including
spotting, prolonged bleeding, skin problems, poor mental health and mood changes, headaches, weight gain,
lowered libido and nausea. The most common side effects mentioned were spotting and prolonged bleeding,
typified by participant 12 (Lothian):
There was blood every day and not much but enough to be annoying, if you know what I mean. So that’s
why I only took one packet and then I stopped because I was just like I can’t . . .
Prior to taking part in the Bridge-it study, 22 of the participants interviewed had previous experiences
of being on regular or long-term contraception, and the majority of them attributed no longer being on
contraception at the time of entry into the study to negative side effects. Therefore, for such participants,
a barrier to regular uptake of contraception was not necessarily access related, but symptom and
well-being related, and such accounts highlight the persistent difficulties faced by some women in
their contraceptive journeys.
Some women described the commitment required to take the POP every day as a barrier to uptake,
particularly in the context of busy lives:
I think as well it can be annoying having to remember every day to take it unless you’re in a really good routine.
Participant 12, Lothian
As well as difficulties in remembering to take the POP during the Bridge-it study, some described
previous experiences of struggling to remember to take oral contraception in the past:
I don’t think it’s hard to access it. I think, like the only thing I have found was just having it at the same
time, like, every day.
Participant 9, London
Missed pills were a common reason for previous EC use, highlighting the recurring issue of user
compliance and how this may act as a barrier to uptake of effective contraception.
Difficulties accessing GP/SRH clinic appointments or finding the time to attend such services to renew
their supply or find an alternative were reported by one-quarter (14/57) of intervention participants.
Some discussed not being able to continue accessing POP through the pharmacy as a barrier to getting
further supplies:
It’s a bit of an annoyance having to do it especially when it’s something that you’ve been on for ages and
you have to almost go back just to get it prescribed.
Participant 12, Lothian
And if I could just . . . because I don’t want to have to book an appointment at the GP, you know . . .
if I could just go to the pharmacy and get something I probably would have done it.
Participant 22, Lothian
Participants also discussed how the embarrassment and shame related to attending SRH clinics may
have acted as a barrier to the rapid-access component of the study:
I think I would rather go to the GP, but only because I feel like it is a little bit of a taboo to say I’m going
to the [SRH] clinic.
Participant 27, Lothian
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Therefore, consistent with these concerns, few intervention participants visited participating SRH clinics
for further contraception (17%, n = 52), with most of those accessing additional POP or alternatives
doing so through their GPs. Such experiences highlight that, although bridging in the pharmacy setting
was pivotal in helping many participants to overcome initial access barriers to routine contraception,
the need to access further supplies/advice in more traditional contraceptive settings created barriers for
some to remaining on effective contraception. Considerations for wider implementation to overcome
such challenges could include greater linkage with general practices in the bridging process, as well as
the feasibility of longer-term contraceptive care in the pharmacy setting.
Although bridging using POP was effective for many in the study, including non-users and previous
users of hormonal contraception, it is important to recognise that it is not a comprehensive solution,
as the remaining barriers highlight. Persistent barriers to uptake relating to well-being and access of
routine effective contraception remain, emphasising the need for a package of solutions to ensure that
all of these diverse different needs are met. Such challenges must be acknowledged to optimise future
implementation, with attention paid to making the process of accessing ongoing contraception post
bridging easier, the provision of a variety of contraceptive options and the need for a central focus on
the importance of well-being during contraceptive consultations. Box 5 provides a summary of key
learning for future implementation.
The impact of context on the Bridge-it study implementation and outcomes
It is important to consider context in implementation and the potential impact that existing contextual
challenges may have on wider implementation.
The pharmacy context: competing priorities and staffing issues
Pharmacists provided insights into their specific pharmacy contexts during training and in interviews.
The pharmacists highlighted potential facilitators of recruitment (e.g. long opening hours, accessibility,
high rates of EC dispensing), as well as barriers to delivery of the Bridge-it study intervention (e.g. time
pressures, lack of resources, competing demands). In particular, issues of time management and
competing priorities seemed to be ingrained in community pharmacy working cultures, with common
narratives emerging around high workloads and expanding roles:
Interviewer: And what do you think are the main challenges of working in your pharmacy?
Pharmacist 8, Tayside: It is time I would say, it is the ever-increasing amount of roles that we have taken
on and having the time to do them properly.
BOX 5 Key learning for future implementation 2
l Provision of a bridging supply of POP with EC from the pharmacy had a positive impact on
contraceptive practices in the short term and, potentially, in the longer term.
l Key mechanisms of change highlighted include ease of access, increased knowledge, awareness,
confidence in accessing contraception and managing risk.
l Persistent barriers to accessing and regularly using routine contraception remain, including worries about
side effects, the ingrained stigma of SRH services and difficulties accessing contraceptive appointments.
l This intervention may work well as part of a package of solutions to increase the uptake of effective
contraception, ensuring that a diversity of different needs are met.
l Suggestions to increase uptake of effective contraception include greater linkage with general practices,
consideration of longer-term contraceptive care in the pharmacy setting, a key focus on side effects and
the importance of well-being in contraceptive consultations.
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Many described a move towards transferring services from general practices, resulting in increasing
responsibilities and pressures on pharmacist time. Such pressures were often exacerbated by a lack of
resources and staffing issues:
. . . it never feels like you have enough people.
Pharmacist 12, Lothian
This seemed to be common across the participating pharmacies, fuelled by staff holidays, understaffing,
high staff turnover and absence. Although such existing challenges at times contributed to low recruitment
rates and a lack of engagement with the Bridge-it study, pharmacists were typically enthusiastic about
embedding bridging into everyday pharmacy practice. However, it is evident that if bridging were widely
implemented as a service, accounts of widespread contextual challenges highlight the need for additional
resources because of the potentially time-intensive nature of such a service.
The sexual and reproductive health clinic context: funding cuts and changing
service provision
Sexual and reproductive health providers described SRH services being overwhelmed by different
contextual factors, including patient needs and demand, staff availability, funding cuts and changing
service provision. Similarly to pharmacy staff, SRH workers described continually trying to manage
priorities to cope with staff shortages:
I think that across the whole of the NHS, resources is a real issue. You know, if staff are off sick,
we kind of struggle to cover things. You know, we’re constantly trying to juggle, and constantly trying to
desperately figure out if we take somebody off this clinic then maybe we could cover that clinic . . .
SRH worker 1, Lothian
Accounts highlighted the impact this could have on meeting patient expectations and needs, in relation
to both the availability of appointments and the time provided for those appointments:
We don’t have enough time for appointments but also, we don’t have enough appointments for the
demand. You know? And because . . . well, you know, services have been cut and staff [have] been cut and
there’s only so much, really, that you can give.
SRH worker 5, London
As well as services being cut, SRH staff also spoke of services being reshaped to accommodate limited
funding and resources. Two sites highlighted a move to triaging and from walk-in clinics to priority
access clinics. An increased focus on young people’s services was evident, as was a move away from
provision of routine contraception to a focus on more specialised services, as indicated by SRH
worker 3 (Tayside):
Because obviously we were providing the more specialist stuff, whereas people that would be looking just
for routine contraception would be encouraged to attend their GPs, rather than come to the specialist
service, just because [of] the lack of capacity.
These existing challenges and practice priorities had potential implications relating to the implementation
of the Bridge-it study intervention and potential wider implementation of bridging as a service. Concerns
were raised relating to SRH services having the resources to cope with rapid-access appointments, as
well as the lack of fit with existing service provision and practice priorities. One SRH worker highlighted
how exceptions to normal practice would be made for research studies:
I think if they showed the card, though, and I’ve had that situation before, it’s slightly different, if they
have evidence that they participate in that study, so that would be slightly different.
SRH worker 2, Lothian
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Despite this, concerns were raised about the potential for Bridge-it study participants to be turned
away or missed because of a lack of fit with current practice:
And although the nurses were trying to get the information from patients if they had been involved in the
Bridge-it study, if the patient didn’t specifically explain that, they probably wouldn’t have been able to get
into the clinic that easily.
SRH worker, Tayside
As already highlighted, this did happen in practice, demonstrating how existing contextual circumstances
in the SRH context influenced implementation in practice. It is also important to consider how a lack of
fit with existing service provision and lack of resources raises issues around how the study would fit in
practice if it were widely implemented as a service in this format. If provision of routine contraception
to all age groups is not a practice priority, it may make it difficult for bridging to become embedded in
routine practice. Some suggested redesigning the study to refer women to general practices instead:
I mean perhaps them going to a general practice setting would be more appropriate than directing them
to sexual health, given the situation that sexual health is in nowadays, if you know what I mean. Because
it is a bit more of a specialist service.
SRH worker 3, Tayside
However, it was also highlighted that this would not be a simple solution because of an already
overburdened general practice service.
Changing contraceptive guidelines and potential impact on policy
Pharmacists raised concerns during training of how the study would fit with existing practices and
changing guidelines relating to EC. Throughout the study period, a number of contraceptive guidelines
were updated, influencing contraceptive practice and, consequently, the implementation of the study.
In March 2018, new EC guidelines came into effect,10 recommending another type of EC, ulipristal
acetate (ellaOne®, HRA Pharma, Paris, France), as the first option rather than LNG. This had an impact on
recruitment, as, if given ulipristal acetate, patients would not be eligible for the Bridge-it study. Some
pharmacists described this new guidance as a barrier to recruitment and stopped recruiting participants:
So because we’d had some additional training with [local SRH clinic] I would always offer people [ulipristal
acetate] rather than [LNG] because some people would just say, you just have to have [LNG], but for me as
a pharmacist and I guess as a woman as well, I would want to be giving the patient the most appropriate
medicine . . .
Pharmacist 19, Lothian
As well as acting as a barrier to recruitment in the Bridge-it study, pharmacists highlighted how this
guidance could have implications for bridging as a practice in pharmacies if widely implemented:
I think with the push towards [ulipristal acetate] that’ll, kind of, throw a spanner in the works for this
idea. Yes. Because it obviously, you’re not going to be able to take it straight away.
Pharmacist 21, Tayside
Box 6 provides a summary of key learning for future implementation.
Process evaluation summary and key implications
Summary of findings
The intervention was acceptable to pharmacists and SRH providers, was seen as an important way
to develop and improve access to contraceptive services, and a way to reduce repeat EC use.
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Pharmacists were generally satisfied with the training received and reported that it prepared them for
delivering the intervention; however, the apparent lack of awareness in SRH centres emphasised the
need for regular communication. Reflections of implementation indicate that the fidelity of delivery
was, on the whole, achieved in the pharmacy context, highlighting adherence to the protocol and the
typically clear and consistent messaging around accessing further contraception. Analysis of screening
log data and pharmacist accounts during interviews shed a light on a variety of barriers to participation
in the study. Some specifically relate to the research context, whereas others are important to consider
with regard to the wider implementation as a service.
Participants’ accounts highlight that providing a bridging supply of POP with EC from the pharmacy
as a practice may have a positive impact on knowledge of contraception and contraceptive practices
in the short term and, potentially, in the longer term through overcoming existing barriers to access,
increasing confidence in accessing contraception and managing risk. The process evaluation highlighted
potential mechanisms of change in helping to overcome some well-established barriers to accessing
longer-term contraception, including ease of access and increased knowledge, awareness of services,
motivation, confidence and perceptions of self-efficacy. However, persistent barriers to accessing and
using routine effective contraception remain, including worries about side effects, concerns about the
commitment required, ingrained stigma related to accessing SRH clinics and difficulties accessing
repeat prescriptions and appointments for continued contraceptive care. Such barriers are important to
consider for future contraceptive trials and in relation to wider implementation of bridging as a service.
A broad range of factors influenced the implementation of the intervention in practice, including the
context of participating pharmacies and SRH clinics, and broader changes to contraceptive guidelines.
A range of cross-cutting challenges to implementation emerged that were specific to the community
pharmacy and SRH context (e.g. high workloads, understaffing and changing priorities), which had
an impact on delivery, with evidence of deprioritisation of screening and recruitment, fatigue with
research procedures and participants being missed or turned away at SRH centres. Implementation
was also influenced by key changes to contraceptive guidelines that had implications for pharmacy
practice. It is important to understand such key contextual challenges to implementation and the
potential impact on outcomes to shed a light on how these issues may be alleviated if bridging were
widely implemented as a service.
Key learning and implications
Why did the intervention work?
The findings from the process evaluation support the conceptual framework underpinning the intervention
that the offer of a bridging contraception during EC consultations along with signposting to SRH services
would encourage and prompt uptake of ongoing effective contraception. As well as having a positive
BOX 6 Key learning for future implementation 3
l Existing challenges in the participating pharmacy and SRH contexts (e.g. lack of resources and changing
practice priorities) influenced implementation of the study in practice, with the deprioritisation of
screening potential participants, fatigue with research procedures and participants being missed or
turned away from SRH centres.
l Updated contraceptive guidance had an impact on recruitment into the study and has potential
implications for the wider implementation of bridging in the current format.
l Suggested learning for wider implementation includes the need for sufficient resources and time to
administer this service, and a need to consider changing service provision in SRH contexts.
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impact on the uptake of effective contraception, the intervention potentially contributed to an impact
for some participants in the longer term through increasing their knowledge of contraception, awareness
of services, and confidence in accessing contraception and managing risk. The process evaluation shed a
light on potential key mechanisms of change, including ease of access, increased knowledge and awareness
of services, motivation and perceptions of self-efficacy. In particular, the convenience and accessibility of
pharmacies seemed pivotal in overcoming some well-established barriers to contraception.
Accounts highlighted an existing demand for greater access to effective contraception through
pharmacies, and the provision of POPs as a bridging method of contraception seemed to be generally
accepted and welcomed by pharmacists, SRH providers and participants, highlighting a synergy
between intervention design and patient need. As well as being acceptable to pharmacists, SRH
providers and participants, bridging as a practice also seemed to be feasible in the pharmacy setting,
despite existing contextual challenges, suggesting that the practice could be widely implemented and
routinely embedded in community pharmacies (albeit with some adaptations to alleviate challenges and
encourage greater uptake).
Although prompting positive change in contraceptive practices for many participants, it is important
to acknowledge that barriers to accessing and remaining on effective contraception persist, including
worries about side effects, ingrained stigma relating to accessing contraception (particularly in SRH
services) and difficulties accessing appointments for continued contraceptive care. Such challenges
require consideration in the design of future contraceptive trials and in the wider implementation of
bridging contraception as a service, and emphasise the need for a package of solutions to ensure that
this diverse range of different needs are met.
Implications for wider implementation
The process evaluation shed a light on important implications for wider implementation of bridging as
a service and these are detailed below. It is important to consider ways to address key implementation
challenges and overcome persistent barriers to accessing and using effective contraception.
Key learning for wider implementation as a service
l Adaptations to the intervention should be made to recognise existing contextual challenges in the
pharmacy and SRH context, changing contraceptive guidelines and recurrent barriers to long-term
use of effective contraception.
l Suggestions to increase uptake of bridging contraception in the pharmacy setting include greater
advertising and promotion of the service, provision of non-judgemental and supportive contraceptive
consultations, an option to book routine contraceptive consultations in pharmacies outside of EC
consultations and increasing the bridging contraceptive options available.
l Suggestions to increase continued uptake of effective contraception include clear and consistent
information provision about further contraceptive access, greater linkage with general practices,
easier processes for obtaining repeat prescriptions and consideration of longer-term contraceptive
care in the pharmacy setting. In addition, there should be a focus on both the side effects and the
importance of well-being during contraceptive consultations.
l Existing contextual challenges in the pharmacy and SRH context, including lack of resources and
changing practice priorities, highlight the need for sufficient resources and time to administer this
service for it to be embedded in routine practice.
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Chapter 6 Discussion of the Bridge-it study
Interpretation
The Bridge-it study demonstrated that this community pharmacist-delivered intervention of provision
of a small bridging supply of oral contraception along with EC and the invitation to a SRH clinic
resulted in a significantly larger proportion of women using effective contraception 4 months later
than standard care alone. The difference in uptake of effective contraception between the groups was
large. Furthermore, significantly fewer women in the intervention group than in the control group
sought EC again during the study. In addition, consistent with the known safety of the POP,20 no
serious adverse events were reported. These findings are clinically important. Given that use of
effective contraception prevents unintended pregnancies, the public health benefit of this simple
and safe intervention is potentially considerable.
Why did the intervention work?
The increase in use of effective contraception at 4 months (1 month after bridging supplies of POP
in intervention group had run out) seemed to be largely related to continued use of the POP, with
further supplies mostly obtained from the GP. There was evidence from the process evaluation that
women who received and used the POP liked it and decided to continue with it. The POP has not
traditionally been a common choice for contraception in the UK. It is estimated to be used by only
5.6%31 of contraception users and is typically reserved for those with contraindications to combined
hormonal contraception.20
Did advice from the pharmacist play a role?
A larger proportion of women in the intervention group recalled that the pharmacist discussed
contraception with them. The proportion receiving contraceptive advice in both groups of the study
was much larger than in our mystery shopper exercise (49% of mystery shoppers received advice),13
suggesting a possible effect of the study on pharmacist behaviour. It is possible, therefore, that the
relative impact of the intervention compared with standard care in ‘real life’ might be greater than
observed in our study.
It was a disappointment that the rapid access invitation to SRH services did not increase the proportion
of women in the intervention group accessing the SRH services compared with the control group. The
rapid access to a SRH clinic was used by fewer than one out of five women in the study and only two
women (< 1%) used the rapid access within 1 month of EC. In our earlier pilot study, 32% of women
used the rapid access to a SRH clinic.12
The process evaluation highlighted some of the difficulties facing SRH services during the study, including
funding cuts to SRH services (London) that may have restricted access for these women. It was also
suggested that many women prefer to access contraception from their GP and that the perceived stigma
of attending a SRH service is still a barrier for some.We had included the rapid-access invitation in
our study design to facilitate access to a specialist contraceptive service where all methods could be
provided. Our earlier pilot study had suggested that this might increase access to and uptake of LARC;15
however, we did not observe this in the current study, in which rates of LARC uptake were similar
between groups. Although the rapid access may help some women to access effective contraception,
the findings do suggest that this may be a less important component of the intervention than the supply
of POP. Given the difficulties facing SRH services and some of the complexities highlighted by the
process evaluation around SRH services being able to make rapid access available, community
pharmacies signposting to contraceptive services may suffice.
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Generalisability and limitations
The Bridge-it study was a well-designed trial, with a sufficiently large sample size to show the expected
effect with sufficient power. The primary outcome findings also remained consistent, even when adjusted
for a range of factors and the missingness of data. The study was conducted at three different sites across
the UK and the trends were consistent at each site. The Bridge-it study findings are also reassuringly
consistent with the findings of our earlier pilot study.15
The pharmacies in the Bridge-it study included a mix of small independent pharmacies and large chain
pharmacies, and so should reflect EC service provision across the UK. In addition, the women who
participated in the Bridge-it study were of similar age and shared similar characteristics to EC users in
previous studies in the UK.32 The findings should therefore be applicable across the UK.
The intervention tested was a simple one (i.e. a 3-month supply of POP provided by PGDs). In addition,
the intervention should not be costly, as POP is an inexpensive drug. However, this will be determined
by our cost-effectiveness analysis.
This was a difficult study to undertake. Pharmacists are not usually familiar with undertaking research.
The pharmacy is a commercial setting. Requiring pharmacists to recruit participants, provide study
information and complete additional paperwork as part of a research study was an added burden to EC
provision. Although cluster randomised trials are generally susceptible to bias as allocation is known to
participants at consent, our pilot study informed us that a study design of individual randomisation in
the community pharmacy setting would not work.15 The study design meant that different groups of
women participated in the two periods. This mix of factors contributed to varying recruitment rates
across pharmacies and between periods, resulting in different lengths of required recruitment and not
all pharmacies successfully recruiting in both periods. Although this added to the complexity of the
study and its management, it produces more robust and generalisable findings.
The main limitation of this study (as for many contraceptive studies) is that the outcome was the uptake
of effective contraception rather than the number of unintended pregnancies. We had originally intended
to examine abortion rates in each group as a co-primary outcome, but during the course of the study it
became evident that we could not recruit sufficient numbers of participants within a realistic time frame,
and so we chose to focus solely on uptake of effective contraception, which required smaller sample size.
Use of effective contraception should prevent unintended pregnancy; however, the association is more
complex, particularly as the use of a method of contraception does not always equate to correct and
consistent use.33 Thousands of participants would have been required for this study to have the power
to demonstrate an effect of the intervention on unintended pregnancies. Although participants gave
consent to allow subsequent data linkage with abortion registries, the sample size may be too small to
show any difference between the groups.
Another consideration is that contraceptive use was self-reported. However, there is some evidence that
women’s self-reporting of contraceptive method is reliable.34 The findings from the limited validation
exercise among those women who both obtained contraception from the SRH clinic and responded to
follow-up showed that 88% of women were provided with the same method as they had reported. This
provides some support for the reliability of self-reporting of contraception. Loss to follow-up for the study
was 35%, which was larger than the 25% we expected. However, there was no differential loss to follow-up
between groups and the characteristics of women with and without follow-up data were similar.
This study was undertaken with EC containing LNG, which was the most commonly used EC at that time
and suitable for immediate start of oral contraception.35 However, any future rollout of the intervention
does not need to be limited to this EC, as it would also be possible for community pharmacists to provide
bridging contraception of the POP containing ulipristal acetate (a more effective EC).36 The only issue
would be that women would be advised to wait 5 days after taking ulipristal acetate before starting the
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POP (rather than immediately or the next day after EC containing LNG) because it has been shown that
starting hormonal contraception sooner than 5 days after ulipristal acetate might potentially impair the
ability of ulipristal acetate to delay ovulation and therefore render EC less effective.10,37,38
Overall evidence
With the exception of our earlier pilot study,15 to the best of our knowledge, the only published study
that examined the uptake of effective contraception after EC offered women (in Jamaica) a discount
on the subsequent cost of contraceptive pills and had no effect on subsequent contraceptive use.14
The only other intervention that has demonstrated a large impact on the use of effective contraception
was the Contraceptive CHOICE Project in the USA,39 in which women requiring contraception in a
range of settings were counselled about LARC and provided with their chosen method free of charge
in a setting where contraception is usually not free. LARC uptake was 67% in the Contraceptive
CHOICE Project cohort, compared with 3% nationally. The Bridge-it study, by comparison, assessed
a simple intervention delivered by community pharmacists at EC request.
Recommendations for research
Future research should be directed at a robust evaluation of the impact of the Bridge-it study
intervention following any wide-scale implementation (to include impact on abortion rates, cost-
effectiveness and on experiences of women and community pharmacists following implementation).
This should be cognisant of existing contextual challenges in the pharmacy and SRH context.
The findings of the Bridge-it study are particularly relevant to the NHS during the current Covid-19
pandemic. Pharmacists are already embedded in SRH care in the UK and could provide an alternative
way for women to access regular effective contraception.40 As part of the NHS Long Term Plan, NHS
England plans to work with the government to make greater use of community pharmacists’ skills and
opportunities to engage patients.41,42 As part of the deal, the NHS is introducing an expanded clinical
role for local pharmacists, beginning ‘a revolution in patient care’ that could see community pharmacy
becoming the first port of call for minor illness and health advice.
Therefore, we propose that future research should also focus on the feasibility, acceptability and
impact of more contraceptive services being delivered from community pharmacies. Our process
evaluation has highlighted the need for sufficient resources for such services to be embedded in
routine practice. In doing so, and alongside appropriate advertising and promotion of the service and
an emphasis on well-being during contraceptive consultations, services could overcome persistent
barriers to accessing and using effective contraception.
Future research should also consider ways to better support research in the community pharmacy setting.
Implications for decision-makers
What if offering a 3-month supply of the progestogen-only pill with emergency
contraception became standard practice throughout the UK?
Emergency contraception users are a group who are at high risk of unintended pregnancy. A subsequent
increase of 20% in contraceptive uptake is a large and clinically important increase. Pharmacy provision
of POP is inexpensive. A 3-month supply of the desogestrel POP costs the NHS approximately £3 and
the estimated cost of the pharmacist’s time is around £30.21,43 Provision of a bridging supply of POP with
EC has received support in surveys of EC users and also from members of the Faculty of Sexual and
Reproductive Healthcare.32,44 In addition to increasing uptake of effective contraception, it is likely
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that widely implementing bridging POP might also reduce rates of repeat EC use (as observed in the
Bridge-it study), which would also generate savings (through reduced consultations for EC).
Some may be concerned that the intervention could discourage use of LARC. However, there were no
significant differences between the two arms of the study in uptake of LARC after EC use. Existing
evidence plus the data from interviews with participants, pharmacists and SRH clinic staff, conducted
as part of the process evaluation, showed that not all woman wish to use LARC45 and many value the
control they have with a method such as a pill, which allows them to start and stop the contraception
themselves. Furthermore, mathematical modelling from the USA suggests that relatively more
unintended pregnancies at population level would be prevented by efforts focused on encouraging
women who are not using an effective contraceptive method to use one (e.g. POP), compared with
switching those already using an effective method to a more effective LARC method.46
We chose to provide the POP as bridging contraception over the more commonly used combined oral
contraceptive pill because the latter has more contraindications and health risks.20 The POP used in the
study (i.e. 75 µg of desogestrel/day) consistently inhibits ovulation in almost all users (in contrast to
older POPs), and so is likely to be as effective as the combined oral contraceptive and is easier to use
as it is taken every day without a break.
This study has enormous implications for public health policy, as it provides evidence for a simple,
effective strategy that could prevent more unintended pregnancies for women.
Unintended pregnancies may end in abortion, but may also result in miscarriage or an unplanned birth.
Better pregnancy planning can improve outcomes for babies and mothers.
Although this intervention has the potential to be cost-effective, this will not be known until the
results of the planned health economics analysis has been completed.
In addition, we are aware of pharmacies in some settings already supplying an oral contraceptive pill
along with EC, yet without any robust evidence to support this practice.17 The Bridge-it study provides
the robust evidence required and also the evidence to support any future wide-scale implementation.
DISCUSSION OF THE BRIDGE-IT STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
Chapter 7 Conclusions
Provision of a bridging supply of POP with EC from a pharmacist clinic provides temporary contraception(POP) to prevent unintended pregnancies from unprotected sex in the same cycle and subsequent cycles.
The provision of a rapid-access card to a SRH clinic was designed to facilitate access to contraceptive services
(SRH clinic), but we did not find evidence that this approach was effective.
The Bridge-it study showed that this intervention resulted in a significant increase in subsequent
reported use of effective contraception, which has the potential to prevent unintended pregnancies
for women after EC. A reduction in unintended pregnancies would also save costs for the NHS and a
cost-effectiveness analysis will report on this.
Evaluation of the impact of this intervention would be important following any future wide-scale
implementation.
Impact of patient and public involvement, challenges of patient and public
involvement and lessons learnt
Pre-funding study design and protocol development
We used the local PPI network at the SRH service in Lothian to help inform and improve the study
design and recruitment plan. We also held small group meetings with women attending our specialist
contraceptive services, teenage mothers attending toddlers groups, pregnant women in the Family
Nurse Partnership programme and members of the local abortion rights group. The study name, protocol
and original Health Technology Assessment programme application were reviewed and approved by the
chairperson and members of the PPI group. The Plain English summary of the application was edited by
a PPI member (a 16-year-old woman) and was improved as a result. We also used our PPI network to
help address questions from the Health Technology Assessment board.
Mystery shopper exercise
We used our PPI members from the TSC and local PPI members at each site to help identify potential
‘mystery shoppers’ for the pharmacy visits.
Trial Steering Committee and key project decisions
Patient and public involvement members commented on the participant information sheet and consent
documentation, and, in response to this, some changes were made and these documents were improved
as a result. The input of the PPI members on key recruitment issues arising during the course of the
study (relating to slower than expected recruitment) was highly valuable, as was their positive voice on
the decision to repower the study on the primary outcome of effective contraception use at 4 months
(confirmed by PPI members as an important outcome for women).
The PPI members have also approved drafts of papers and reports. The PPI network (including a
17-year-old woman) and the PPI representatives on our TSC also made suggestions to improve the
Plain English summary in this report.
Dissemination
The PPI members will be involved in dissemination of the main study findings through their networks
and social media.
The findings of the mystery shopper exercise have already been published13 (online early) and a PPI
member is writing a patient opinion piece to be submitted to the same journal and hopefully published
alongside this.
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Appendix 1 Supplemental table
TABLE 16 Process evaluation data integration table
Source Implementation Mechanisms of impact Context
Qualitative interviews Provider acceptability:














timing suitable; content and
resources adequate. Most felt
that training prepared them
for delivery, but could have
benefited from pharmacist
expertise and role-play and
refresher sessions. SRH staff
received no formal training so






barriers included lack of
time/embarrassment; and
not wanting to take POP/
hormonal contraception.
Suggestions to alleviate













regarding the study aim was




as ‘prompt to change
contraceptive practices’.
Helped to overcome existing
barriers (avoidance, lack of














had positive/no side effects;
found it easy to access
further contraception;
familiarity. Some on effective
contraception post study
had no prior experience on
contraception (due to lack
of need and access barriers),
whereas a small number had
previous negative experiences
and found POP suitable
Participants not on effective
contraception because of a
range of reasons: personal
circumstances (e.g. not
sexually active, no partner,
pregnant or planning
pregnancy); worries and




because of busy schedules/
forgetting; difficulties
accessing GP/SRH clinics
or finding time to attend.
Side effects from HC
commonly mentioned as
barrier post study and pre
study. Twenty-two women
interviewed said they were
not on contraception pre





priorities, high workloads, lack
of resources and expanding
roles. Pressures exacerbated
at particular times (e.g. in
winter, flu clinics take priority).
Existing challenges had an
impact on delivery, with
deprioritisation of screening at
busy times. New contraceptive
guidelines regarding ulipristal
acetate acted as a barrier
to delivery for some and





bridging as a service
SRH context: existing
challenges across sites
included lack of resources,
funding cuts and changing
service provision. Services
being cut and reshaped
(two sites moved to providing
walk-in consultations only to
those who were triaged as a
priority). Focus moved away
from provision of routine
contraception to young
people and specialised
services. Some worried that
participants might be turned
away/missed because of
a lack of fit with practice
priorities and a lack of
resources. Some suggested
sending to general practices
instead
Broader cultural context:
most participants did not
express being consciously
aware of any media coverage
about contraceptives.
Participants mostly described
seeing coverage relating to
the new male contraceptive
pill, and articles focusing on
negative side effects and
general ‘horror stories’.
Some did talk about media
continued
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TABLE 16 Process evaluation data integration table (continued )
Source Implementation Mechanisms of impact Context
Fidelity of delivery (SRH




struggled to get further
contraception), reporting
lack of awareness, being
advised to attend a general
practice and clinics being
too busy
Not being able to get further
contraception through
pharmacies was a barrier.
Embarrassment/shame of
accessing contraception
from SRH clinics commonly
mentioned
coverage leading to particular
contraceptives potentially
getting negative reputations






Fidelity of delivery: 90%
(n = 178) of intervention






could not recall being given
a rapid-access card. Most
were seen at SRH clinic in
< 1 hour (15/25). Sixty-four
per cent (16/25) had smooth
experiences of the rapid-





their GP (74/141) (vs. from
SRH, 21/141). Only 17%
of women attended the
participating SRH centre
and 50% preferred accessing
contraception from a GP.
Thirty-two per cent of women




(screening logs): not willing to
give contact details and be
followed up (54%, 264/490);
not willing to give identifying
data sufficient to allow data
linkage with NHS registries
(54%, n = 262); already
using a hormonal method of
contraception (32%, n= 156);
does not require EC (19%,
n= 93); and does not have
capacity to give informed






follow-up – POP, 36%
(71/198); combined pill/
patch/ring, 14% (28/198); and
LARC methods, 7% (13/198).
Forty-four per cent (88/198)
of intervention participants
were not on effective
contraception at 4-month
follow-up
Reasons for not using
effective contraception
at 4 months: not currently
sexually active, 47% (27/57);
worries about side effects,
21% (12/57); not decided on
method to use, 16% (7/57);
difficult to get appointment
with GP or a SRH clinic, 14%
(8/57); and difficult to find
time to get to GP or a SRH
clinic, 11% (6/57)
Eighteen per cent (35/198) of
women did not use any POP
because of worries about side
effects (29%, 10/35); they
were not with a regular
partner (23%, 8/35); they
did not require regular
contraception (20%, 7/35);
or they preferred to start
another contraceptive
(17%, 6/35)
For those who took POP,
main reason for stopping
before supply ran out: side
effects (25%, 40/158) and
started another method
(4%, 6/158)
Ten per cent (20/198) of
intervention participants
had used EC post study vs.
18% (37/208) of control
participants
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TABLE 16 Process evaluation data integration table (continued )




most (n = 27) training
conducted in pharmacies
(e.g. consultation/training/
break rooms) and seven were
at SRH sites. On average,
one to three pharmacists








mostly relating to contextual
factors (e.g. lack of time) that





study and engaged well
with content, asking for
clarification if unsure.
Most seemed confident
and accepting of their role.
Implementation concerns
included lack of staff/
resources, volume of




reluctance to take POP,







> 30 ECs per month, but
adapted to consider those
dispensing < 30 ECs per
month to include more
independent pharmacies/
increase recruitment
Barriers to selection: low EC
dispensing, charging for EC,
commissioned for bridging,
lack of interest and too busy
Pharmacists’ perspectives:
sought-after service, real
demand for easier access
through pharmacies, often
have patients looking for
this service
Highlighted additional
benefits: raising awareness of
local sexual health clinics and
awareness of testing services
Training sessions, at times,
provided insights into other








lack of resources and reliance
on locums as potential
barriers to delivery
continued
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TABLE 16 Process evaluation data integration table (continued )






March 2018 – new EC
guidelines recommending
ulipristal acetate (ellaOne)
as first option. If this was
provided, then the woman
was no longer eligible for
study. October 2018 – new
weight guidance requiring
double dose of LNG if
weight > 75 kg
Media coverage of
contraception: July 2017–










contraception (e.g. barriers to
access and use); contraceptive
behaviour trends; and general
informative pieces. Sustained
coverage on negative side
effects and personalised
‘horror stories’ detailing fatal
or life-threatening impacts.
Over the 3-year study period,
the number of articles almost
tripled, from 35 in 2017 to
94 in 2019. A prominent
and relevant story during the
study was the widespread
coverage relating to the cost
and accessibility of the pill
in a major chain pharmacy in
the UK (n = 64), which was
criticised for refusing to reduce
EC cost for fear of ‘incentivis
[ing] inappropriate use’.47 The
pharmacy subsequently said it
‘sincerely’ apologised for its





Initial set-up took longer




Finalising PGDs and SS for
each site was time-consuming
and problematic, complicated






particularly in busy periods,
and research staffing issues
Research nurses from all sites
reported receiving few e-mail
responses and having to
spend a substantial amount
of effort on the ground to
encourage pharmacists to
Pharmacists reported a decline
in EC requests during the




Slow recruitment was fuelled
by understaffing, reliance on




submitted to allow new
weight guidance to be
part of study; however,
changing guidance did cause
some confusion and some
pharmacists continued to
exclude potential participants
based on this new guidance
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TABLE 16 Process evaluation data integration table (continued )
Source Implementation Mechanisms of impact Context
recruit, retrain and assist with
paperwork. Reported evident





Owing to commissioning of a








and was seen as an important
way to improve access
to contraception and to
reduce repeat EC use.
Training was considered







of their role in the study
and felt prepared for
delivery, although some had
concerns relating to workload
pressures. Fidelity of delivery
was mostly achieved in the
pharmacy context, with
typically clear and consistent
messaging around accessing
further contraception.
Accounts highlighted a lack
of awareness in SRH centres
and participants reported
unsatisfactory experiences,
indicating the need for
greater integration of all
services involved. A variety
of barriers to participation
were highlighted, some
specific to the research
context and others relevant
to wider implementation
(e.g. embarrassment,
reluctance to take POP)
Bridging may have a positive
impact on contraceptive
practices and knowledge in
the short term and potentially
longer term. Potential key
mechanisms of change




and managing risk. A key
mechanism specific to the
pharmacy setting was ease of
access. Accounts highlighted
the real need and demand
for this service, suggesting
synergy in intervention design
and patient need. Persistent
barriers to accessing and
regularly using routine
contraception remain,
including worries about side
effects, ingrained stigma of
SRH services and difficulties
accessing contraceptive
appointments. Although the
study was effective for some
(including non-users and
previous users), it was not a
comprehensive solution and
the remaining challenges
highlight the need for a
package of solutions to
ensure that their diverse
range of needs are met
A broad range of contextual
factors influenced the
implementation of the study,
including the context of
participating pharmacies and
SRH centres, broader policy
and cultural factors, and the
research context. Existing
challenges in provider




the study, with screening
deprioritisation and
participants being missed
or turned away from SRH
centres. Such existing
challenges meant a high level
of in-person study support
was required to motivate staff
to recruit. Despite challenges,
pharmacists were enthusiastic
about embedding bridging as
routine practice; however,
accounts highlight the need
for additional resources
because of existing time
pressures. There was sustained
negative media coverage of
contraception during the





an impact on recruitment to








contraception in the pharmacy
setting and overcome barriers
to participation include
greater advertising and
promotion of the service;
provision of non-judgemental
and supportive contraceptive









linkage with general practices,






in the pharmacy and SRH
context, including lack of
resources and changing
practice priorities, highlight
the need for sufficient
resources and time to
administer this service for
bridging to be embedded in
routine practice
continued
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TABLE 16 Process evaluation data integration table (continued )
Source Implementation Mechanisms of impact Context
outside of EC consultations;
and increasing the bridging
contraceptive options
available
Learning for future trials:
need for streamlined process
with condensed paperwork,
adequate staff for in-person
support, and integration
and regular communication
with all services involved in
implementation and delivery
Challenges in study set-up
and implementation highlight
the importance of flexibility
and adaptability, and the
importance of in-person
support from study staff
throughout
HC, hormonal contraception; KCH, King’s College Hospital; SS, Service Specification.
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Appendix 2 Process evaluation topic guides
Bridge it Process Evaluation – In depth Interview Guides 
Pharmacists – Topic Guide
Introduction 
Explain the study; emphasise no right/wrong answers; ensure informed consent is ongoing; 
remind participant they can withdraw at any time or choose not to answer any question. 
General background (1)
Age 
Professional backgrounds (probe: length of service as pharmacist and in current
pharmacy)
Previous training in similar interventions 
Pharmacy information (2) 
Description of pharmacy (probe: size, type, location, services provided, typical day, 
working conditions; challenges)
Description of typical EC provision in pharmacy and local area (probe: scope of
distribution/activity, challenges; gaps; potential improvements)
Pharmacists’ perceptions of women requesting EC (probe: typical clientele, positives, 
negatives)
Clarity and consistency of training and Bridge it intervention materials (3) 
How were you trained for the study? 
How did you find the training? (probe: positives, negatives, gaps, potential 
improvement)
What are your views on the training manual? (probe: positives, negatives, gaps, 
potential improvement) 
 Confidence in delivering the Bridge it intervention and adhering to the protocol/training
manual (probe: positives, negatives, gaps, challenges, concerns)
o How well do you think the training prepared you for delivering the Bridge-it 
intervention? Could it have prepared you more? 
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o Were you confident that you would be able to deliver the intervention as asked,
or did you have any concerns? 
Intervention delivery (4) 
Experiences of delivering the intervention and challenges faced (probe 
standard/intervention phase)
o Could you tell me about your experiences of delivering the intervention in
practice? 
o Has it been more/less difficult that you had imagined it would be? 
o What do you think worked well/hasn’t worked well?
o Barriers/facilitators to delivering the intervention (probe: positives, negatives, 
gaps, potential improvement) 
o Could you describe any support you received from study staff?
 Consistency in delivering the Bridge it intervention and adhering to the protocol/training
manual (probe: If not, when, and why not?) 
Describe how the intervention was introduced and delivered in practice
o How did you find screening as a process? (probe: barriers/facilitators)
o What was your decision-making process relating to approaching individual
women about the intervention? Did you approach all/only some? Why?
o Did you develop a pattern in how you approached recruitment and the 
paperwork involved? 
o How did you find using the database?
o On average, how long did the whole process take? 
From your perspective, how well did the Bridge it intervention fit in with day-to-day
pharmacy service provision?  
How well did it fit with current pharmacy guidelines for EC distribution?
Did it raise any unexpected issues relating to day-to-day pharmacy service provision? 
Women’s response to the Bridge it intervention (5) 
Perceived facilitators/ barriers to women’s participation in the Bridge it study (probe
standard care/intervention phase)
o Were women receptive towards the study? Why? Why not?
o What do you think facilitated participation in the study?
o What do you think prevented participation?
o How do you think we could improve participation?
What, if any, positive effects do you think the Bridge it intervention had? 
What, if any, negative effects do you think the Bridge it intervention had? 
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Acceptability of the intervention (6) 
What were your reasons for taking part in the intervention? 
What, if anything, did you find particularly positive about being involved in the Bridge it
study? 
What, if anything, did you find particularly negative about being involved in the Bridge it
study? 
Would you volunteer again for a similar role in the future? [Probe: why?] 
How could we improve the pharmacist role? 
Suggested changes to the Bridge it intervention if it were to be more widely
implemented? 
Other (7) 
Have you been aware of any relevant  media coverage around contraception?
Are you aware of any changing pharmacy guidelines/policy that may impact the 
study/future EC provision?
Closing 
Provide summary of interview discussion 
Ensure interviewee has opportunity to add comments/ask questions
 Seek feedback on the interview experience
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SRH Providers – Topic Guide
Introduction 
Explain the study; emphasise no right/wrong answers; ensure informed consent is ongoing; 
remind participant they can withdraw at any time or choose not to answer any question. 
General background (1)
Tell me a little bit about your professional background (probe: current role etc)
Previous involvement in similar interventions
SRH centre information (2) 
Could you tell me a bit more about the SRH service you work in? (probe: size, location, 
clientele, services provided, typical day, working conditions, challenges)
Description of typical EC/contraceptive provision in SRH service and local area (if not 
covered) (probe: scope of distribution/activity, existing challenges; gaps; potential 
improvements) 
Perceptions of women requesting EC (probe: typical clientele, positives, negatives)
The next set of questions focus on the Bridge-it study 
Awareness of the Bridge it intervention (3) 
How did you find out about the Bridge-it study? 
What are your thoughts on the Bridge-it study? [Probe: positives, negatives, gaps, 
potential improvement] 
Experiences of Bridge-it intervention and challenges faced (4) 
Could you tell me a bit about your experiences so far relating to the Bridge-it study? 
From your perspective, how well does the Bridge it intervention fit in with day-to-day
SRH service provision?
Has it raised any unexpected issues/challenges? 
What do you think has worked well? 
How do you think this could be improved?
Was there support from within your workplace?
Women’s response to the Bridge it intervention (5) 
From your perspective, did women attend SRH service after attending the pharmacy 
for EC? 
o Did Bridge it participants attending SRH for follow up bring their Bridge it study 
card with them? 
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o Had participants used their POP supply (probe: If not, when not and why not?)
Do you think women generally were receptive towards the study? Why? Why not?
Do you think there are any ways we could improve participation?
Did Bridge it participants start effective contraception at SRH? (probe: If not, when not 
and why not?; barriers/challenges to uptake of effective contraception]
What, if any, positive effects do you think the Bridge it intervention had? (probe: on the 
service, on women]
What, if any, negative effects do you think the Bridge it intervention had? (probe: on the 
service, on women)
Acceptability of the intervention (6) 
What, if anything, did you find particularly positive about being involved in the Bridge it
study? 
What, if anything, did you find particularly negative about being involved in the Bridge it
study? 
How could we improve the SRH service provision role? 
Suggested changes to the Bridge it intervention if it were to be more widely
implemented? 
Other (7) 
Were you aware of any relevant media coverage related to contraception that might 
have influenced participation in the study/attitudes to contraception? 
Are you aware of any changing policy/guidelines that might impact your service/future
contraceptive provision?
Closing 
Provide summary of interview discussion 
Ensure interviewee has opportunity to add comments/ask questions
 Seek feedback on the interview experience
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Bridge it Participants – Topic Guide
Introduction 
Explain the study; emphasise no right/wrong answers; ensure informed consent is ongoing; 
remind participant they can withdraw at any time or choose not to answer any question. 
General background (1)
Age 
Life circumstances (i.e. relationships, family etc) 
Area of residence, who living with (ie. family, partner, friends, homeless) 
Employment / education 
Contraceptive use (2) 
The wider context of their lives and experiences of using EC/contraception 
o Previous experience of EC use / unprotected sex (before/after EC use)
o Previous contraceptive use 
o Previous pregnancies/abortions 
Decision making process – what kind of things have influenced your contraceptive use,
what did you consider when making decisions about contraceptive use? 
Influence of others (i.e. family, friends, healthcare providers etc)
Request for EC (3) 
Do you mind telling me a bit about why you requested EC at the time of recruitment to
the Bridge it study (probe: unprotected sex, contraceptive failure, unplanned sex)
Decision making process – what factors considered in deciding to use EC? 
Influence of others (i.e. family, friends, healthcare providers etc)
Decision to attend the pharmacy to request EC – what factors considered in deciding to
use EC? 
Why that particular service/pharmacy? 
Recruitment to the Bridge it study (4) 
How were you recruited into the study?
What did you understand about why we were doing the study?
o  What it was about?
o Why you were invited to take part?
Did you understand what would be involved in taking part?
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
What information did the pharmacist provide you with about taking part in the study? 
(probe: verbal, written, other? Was it clear?) 
Reflections on experience of participating in the intervention in pharmacy (5) 
What information did the pharmacist provide you with about starting contraception after 
EC? (probe: verbal, written, other?)
What information did the pharmacist provide you with about where to get contraception 
after EC? (probe: verbal, written, other?)
What information did the pharmacist provide you with about using the supply of the 
POP? (probe: verbal, written, other)
What information did the pharmacist provide you with about using the ‘study card’ that
participants show at the local sexual health clinic to get a quick appointment? (probe: 
verbal, written, other) 
Reflections on experience of using EC/POP (6) 
Experience of using the EC that the pharmacist gave you (probe: positives, negatives,
when?)
Experience of using the POP that the pharmacist gave you (probe: positives, negatives,
when/for how long? If stopped or didn’t take it, why?)
Decision making process – what factors considered in deciding to use/not to use POP?
Influence of others (i.e. family, friends, healthcare providers etc)
Reflections on experience of accessing SRH service (7) 
Did you attend SRH service after attending the pharmacy for EC? 
o Did you take your Bridge it study card with you? (probe: If not, why not?) 
o What was your experience of the rapid access appointment? (probe: positives, 
negatives, potential improvement)
Decision making process – what factors considered in deciding to attend SRH service? 
Influence of others (i.e. family, friends, healthcare providers etc)
What information did the SRH provider provide you with about starting effective 
contraception? [probe: verbal, written, other?)
Did you start your preferred method of contraception at SRH? (probe: If not, why not)
Subsequent contraceptive use (8) 
Are you still using the method of contraception you received at SRH/GP? (probe: If not, 
why not)
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From your perspective, what are the barriers/challenges to uptake of effective 
contraception?
Acceptability of the intervention (9) 
What, if anything, did you find particularly positive about being involved in the Bridge it
study? 
What, if anything, did you find particularly negative about being involved in the Bridge it
study? 
Did the intervention prompt any change and/or any negative or unintended 
consequences for you? (probe: Any negative outcomes, difficulties, challenges?)
Implementing the Bridge it intervention (10)
From your perspective, how well did the Bridge it intervention fit in with your day-to-day
life? 
Did it raise any unexpected issues relating to your day-to-day life?
How could we improve the Bridge it intervention if it were to be more widely
implemented? 
Other (11)
Were you aware of any media coverage around contraceptive use/pharmacies? (a) 
Are there any other issues regarding the Bridge it study that you would like to talk
about? 
Closing 
Provide summary of interview discussion 
Ensure interviewee has opportunity to add comments/ask questions
 Seek feedback on the interview experience
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Appendix 3 Baseline questionnaire
Baseline Questionnaire 
We would be very grateful if you would spend some time filling out this confidential 
questionnaire. It should take you about 5 minutes. The questionnaire asks about your
background, pregnancy and previous use of contraception.
Completion of this is voluntary and you don’t have to answer this questionnaire or any 
question in it if you don’t want to – it is entirely your choice.
Q1. What is your date of birth? ___/____/______  (dd/mm/yyyy)  
Q2. Tick all the methods of contraception that you have ever used: 
Combined hormonal contraceptive pill/ patch or ring i.e. contain two 
hormones e.g. Microgynon, Ovranette, Evra patch, Nuvaring 
 Progestogen only pill (mini pill) e.g. Cerazette, Noriday 
 Male condom
Contraceptive injection’ jab’ (Depo Provera or Sayana) 
 Implant (Nexplanon)
Copper Coil/intra-uterine device (IUD) 
 Intrauterine system (Mirena or Jaydess or IUS)
Female condom
Cap/diaphragm 
Partner has been sterilised (vasectomy)
 I have been sterilised 
Withdrawal method
Natural family planning (monitoring of temperature, calendar, urine tests etc)
 Other method of protection (please say what) ………………
⬜ I have never used any method
(Please tick)
Q3. Have you ever given birth? Yes No
Q4. Have you ever had a termination (abortion)? Yes No
Q5. Have you ever had a miscarriage?  Yes No
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Q6. Have you ever an ectopic pregnancy?  Yes No
Q7. Are you in an ongoing sexual relationship with a man? 
Yes  No Unsure
Q8. Is this the first time you have taken the  emergency contraceptive pill? 
(please tick box) 
 Yes 
No please state number of times taken in the last 12 months ………
Q9. Which of the following best describes your ethnic background? (please tick 
box) 
White (UK, Irish or any other white background)
Asian or Asian British (Bangladeshi, Indian, Pakistani or any other Asian
Background)
Black or Black British (African, Caribbean or any other Black background)
Mixed or any other ethnic background (please say what) …………….
Thank you for taking the time to complete this questionnaire. Your participation is much 
appreciated.
Please indicate how you would like to receive your £10 voucher:
By phone (please insert number)……………………
By email (please insert email)…………………………
By post (please insert address)…………………………
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Appendix 4 Four-month questionnaire for
control group
Telephone interview- CONTROL
Name of interviewer…………………… Date of
1st call (dd/mm/yy)….
Comment: no answer/left message/text sent requesting call back/other 
Date of 2nd call (dd/mm/yy)
Comment: no answer/left message/ text sent requesting call back/ other 
Date of 3rd call (dd/mm/yy)*
Comment: no answer /left message/ text sent requesting call back/ other Date of
interview (dd/mm/yy)…………………………………………….
Instructions for research nurse:
Verify that the person answering the telephone is the correct individual
Introduce yourself; say that you are the research nurse for the Bridge-it 
study
Remind the participant what project is about and tell her that this is a short 
telephone interview (approx. 10 mins) 
Check that she is still willing to participate.
Remind her that she is under no obligation to answer any or all of the 
questions 
Say that you are very grateful for her help.
Check that it is a convenient time for her to speak. If not rearrange a 
suitable date/time. (Re- scheduled for (dd/mm/yy)…… @.........hrs)
At END of interview:
Thank her for participating
Remind her of the study website details where results of study will be 
posted 
Ask if she would like a copy of results of the study at the end
verify whether by text/email/postal address (select)
Check that you have the most up to date phone/email/postal address 
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Check if she consented to the detailed telephone interview (60 mins) : still 
willing to participate in the telephone interview? 
No Yes
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4 Month Questionnaire - CONTROL
We would be very grateful if you would spend some time filling out this anonymous 
questionnaire. It should take you about 10 minutes. Completion of this is voluntary and
you don’t have to answer this questionnaire or any question in it if you don’t want to – it is
entirely your choice. 
Section A. Information at the pharmacy and contraception
1. What method of contraception (if any) were you using at the time when you went
to get EC from the pharmacy ? (Please tick)
None
Condoms
Other (please write it here)…………….
2. Did you take the EC that the pharmacist gave you?
Yes
No
If No, (please tell us why not)……………………………
3. Did the pharmacist provide you with any information about starting




Both written and verbal information
4. Did the pharmacist provide you with any information about where to get




Both written and verbal
5. What method or methods of contraception (if any) are you using now?
(Please tick all that apply)
DOI: 10.3310/hta25270 Health Technology Assessment 2021 Vol. 25 No. 27
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Cameron et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79
Combined hormonal contraceptive pill / patch or ring
Progestogen only pill (mini pill)
Male condom 
Contraceptive injection’ jag’ (Depo Provera or Sayana)
Implant (Nexplanon) 
Copper Coil/intra-uterine device (IUD) 
Intrauterine system (Mirena or Jaydess)
Female condom
Cap/diaphragm 
Partner has been sterilised (vasectomy) 
I have been sterilised 
I am currently pregnant 
Other method of protection-please write here what this is ………………
I am not using any method of contraception (Please go to question 8) 
6. When did you start using this/these contraceptivemethod(s)?
(Please tick)
The same day that I took the EC
The day after I took the EC
With the start of my next period after the EC
Other – please specify the approximate date (dd/mm/yyyy) 
7. Where did you get the current method(s) of contraception that you are using from
(Please tick all that apply)
GP clinic
Family planning/ sexual health clinic
Other -please tell us where you got contraception from………………
Please go to question 9 now
8. Please tell us why you are not using a method of contraception? (Please tick all that
apply
Not currently sexually active
I am worried about side effects with contraception 
I cannot use contraception due to medical reasons 
I am not decided on what method I want to use 
Difficult to get an appointment for GP or family planning/sexual health clinic
appointment 
Difficult to find time to get to GP or family planning/sexual health clinic appointment 
I am trying for a baby
Other - please tell us why………………
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9. Have you used EC any further time(s) since entering the study? (Please tick)
No
Yes- please tell us how many times approximately……..
10. Have you been pregnant since you entered the study 4 months ago?
No (Go to question 17)
Yes
if Yes, please tell us about all of the pregnancies you have had since
you entered the study 4 months ago (Please tick all that apply)
I am currently pregnant
I had a miscarriage
I had an abortion
I had an ectopic
Other - please tell us………………
11. Below are some questions that ask about your circumstances and feelings around
the time you became pregnant. Please think of your current (or most recent)
pregnancy when answering the questions below.
In the month that I became pregnant...... 
(Please tick the statement which most applies to you): 
I/we were not using contraception
I/we were using contraception, but not on every occasion
I/we always used contraception, but knew that the method had failed (i.e. broke,
moved, came off, came out, not worked etc) at least once
I/we always used contraception
12. In terms of becoming a mother (first time or again), I feel thatmy
pregnancy happened at the......
(Please tick the statement which most applies to you): 
right time
ok, but not quite right time
wrong time
13. Just before I became pregnant.......
(Please tick the statement which most applies to you): 
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I intended to get pregnant
My intentions kept changing
I did not intend to get pregnant
14. Just before I became pregnant....
(Please tick the statement which most applies to you)
I wanted to have a baby
I had mixed feelings about having a baby
I did not want to have a baby
In the next question, we ask about your partner - this might be (or have been) your
husband, a partner you live with, a boyfriend, or someone you’ve had sex with once 
or twice.
15. Before I became pregnant....
(Please tick the statement which most applies to you)
My partner and I had agreed that we would like me to be pregnant
My partner and I had discussed having children together, but hadn’t
agreed for me to get pregnant
We never discussed having children together
16. Before you became pregnant, did you do anything to improve your health in
preparation for pregnancy?
(Please tick all that apply) 
Took folic acid
Stopped or cut down smoking
Stopped or cut down drinking alcohol 
Ate more healthily
Sought medical/health advice 
Took some other action, please describe …………………… or
I did not do any of the above before my pregnancy
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17. Have you had any hospital admissions in the last 4 months since you
participated in the Bridge-it study? (Please tick)
No
Yes
If you have answered yes to this question, then the study research will need to call you to get 
more details. 
Please return this questionnaire in the envelope provided to: 
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Appendix 5 Four-month questionnaire for
intervention group
Telephone interview - INTERVENTION
Name of interviewer…………………… Date of
1st call (dd/mm/yy)….
Comment: no answer /left message/ text sent requesting call back/ other 
Date of 2nd call (dd/mm/yy)
Comment: no answer /left message/ text sent requesting call back/ other 
Date of 3rd call (dd/mm/yy)*
Comment: no answer /left message/ text sent requesting call back/ other Date of
interview (dd/mm/yy)…………………………………………….
Instructions for research nurse:
Verify that the person answering the telephone is the correct individual
Introduce yourself; say that you are the research nurse for the Bridge-it 
study
Remind the participant what project is about and tell her that this is a short 
telephone interview (approx. 10 mins) 
Check that she is still willing to participate.
Remind her that she is under no obligation to answer any or all of the 
questions 
Say that you are very grateful for her help.
Check that it is a convenient time for her to speak. If not rearrange a 
suitable date/time. (Re- scheduled for (dd/mm/yy)…… @.........hrs)
At END of interview:
Thank her for participating
Remind her of the study website details where results of study will be 
posted 
Ask if she would like a copy of results of the study at the end
verify whether by text/email/postal address (select)
Check that you have the most up to date phone/email/postal address 
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Check if she consented to the detailed telephone interview (60 mins) : still 
willing to participate in the telephone interview? 
No Yes
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4 Month Questionnaire - INTERVENTION
We would be very grateful if you would spend some time filling out this anonymous 
questionnaire. It should take you about 10 minutes. Completion of this is voluntary and
you don’t have to answer this questionnaire or any question in it if you don’t want to – it is
entirely your choice. 
Section A. Information at the pharmacy and contraception
1. What method of contraception (if any) were you using at the time when you went
to get EC from the pharmacy? (Please tick)
None
Condoms
Other (please write it here)…………….
2. Did you take the EC that the pharmacist gave you?
Yes
No
If No, (please tell us why not)……………………………
3. Did the pharmacist provide you with any information about starting




Both written and verbal information
4. Did the pharmacist provide you with any information about where to get




Both written and verbal
5. What method or methods of contraception (if any) are you using now?
(Please tick all that apply)
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Combined hormonal contraceptive pill / patch or ring
Progestogen only pill (mini pill)
Male condom 
Contraceptive injection’ jag’ (Depo Provera or Sayana)
Implant (Nexplanon) 
Copper Coil/intra-uterine device (IUD) 
Intrauterine system (Mirena or Jaydess)
Female condom
Cap/diaphragm 
Partner has been sterilised (vasectomy) 
I have been sterilised 
I am currently pregnant 
Other method of protection-please write here what this is ………………
I am not using any method of contraception (Please go to question 8) 
6. When did you start using this/these contraceptivemethod(s)?
(Please tick)
The same day that I took the EC
The day after I took the EC
With the start of my next period after the EC
Other – please specify the approximate date (dd/mm/yyyy)
7. Where did you get the current method(s) of contraception that you are using from
(Please tick all that apply)
GP clinic
Family planning/ sexual health clinic
Other -please tell us where you got contraception from………………
Please go to question 9 now
8. Please tell us why you are not using a method of contraception? (Please tick all that
apply
Not currently sexually active
I am worried about side effects with contraception 
I cannot use contraception due to medical reasons 
I am not decided on what method I want to use 
Difficult to get an appointment for GP or family planning/sexual health clinic
appointment 
Difficult to find time to get to GP or family planning/sexual health clinic appointment 
I am trying for a baby
Other - please tell us why………………
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9. Have you used EC any further time(s) since entering the study? (Please tick)
No
Yes- please tell us how many times approximately……..
10. Have you been pregnant since you entered the study 4 months ago?
No (Go to question 17)
Yes
if Yes, please tell us about all of the pregnancies you have had since
you entered the study 4 months ago (Please tick all that apply)
I am currently pregnant 
I had a miscarriage 
I had an abortion
I had an ectopic 
Other - please tell us………………
11. Below are some questions that ask about your circumstances and feelings around
the time you became pregnant. Please think of your current (or most recent)
pregnancy when answering the questions below.
In the month that I became pregnant...... 
(Please tick the statement which most applies to you): 
I/we were not using contraception 
I/we were using contraception, but not on every occasion
I/we always used contraception, but knew that the method had failed (i.e. broke,
moved, came off, came out, not worked etc) at least once
I/we always used contraception 
12. In terms of becoming a mother (first time or again), I feel thatmy
pregnancy happened at the......
(Please tick the statement which most applies to you): 
right time
ok, but not quite right time
wrong time
13. Just before I became pregnant.......
(Please tick the statement which most applies to you): 
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I intended to get pregnant 
My intentions kept changing
I did not intend to get pregnant 
14. Just before I became pregnant....
(Please tick the statement which most applies to you): 
I wanted to have a baby 
I had mixed feelings about having a baby 
I did not want to have a baby 
In the next question, we ask about your partner - this might be (or have been) your
husband, a partner you live with, a boyfriend, or someone you’ve had sex with once 
or twice.
15. Before I became pregnant....
(Please tick the statement which most applies to you):
My partner and I had agreed that we would like me to be pregnant 
My partner and I had discussed having children together, but hadn’t agreed for 
me to get pregnant 
We never discussed having children together
16. Before you became pregnant, did you do anything to improve your health in
preparation for pregnancy?
(Please tick all that apply) 
Took folic acid
Stopped or cut down smoking 
Stopped or cut down drinking alcohol
Ate more healthily
Sought medical/health advice
Took some other action, please describe ………………………. or
I did not do any of the above before my pregnancy
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17. Have you had any hospital admissions in the last 4 months since you
participated in the Bridge-it study? (Please tick)
No
Yes 
If you have answered yes to this question, then the study research will need to call you 
to get more details.
Please return this questionnaire in the envelope provided to: 
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